
<!DOCTYPE html>
<html dir="ltr" lang="en">
<head>
 
<link rel="preconnect" href="https://cdn.cookielaw.org">
<link rel="preconnect" href="https://www.googletagmanager.com">
<link rel="dns-prefetch" href="https://www.google-analytics.com">
<link href="https://cdn.cookielaw.org/scripttemplates/otSDKStub.js" rel="preload" as="script">
 <link href="https://www.googletagmanager.com/gtm.js?id=GTM-5MKXR9" rel="preload" as="script">
<!-- OneTrust Cookies Consent Notice start --> 
<script src="" type="text/javascript" charset="UTF-8" data-domain-script="7a4eae6f-1f57-4f7c-8a64-5aa159ee745e"></script>
<script type="text/javascript">
function OptanonWrapper() { }
</script>
<!-- OneTrust Cookies Consent Notice end -->
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta lang="en">
<meta http-equiv="content-type" content="text/html; charset=utf-8">
<meta http-equiv="content-language" content="en">
<meta name="viewport" content="width=device-width, height=device-height, initial-scale=1, minimum-scale=1, maximum-scale=5, user-scalable=1">
 <!-- Title and Description -->
 <title>Drugs for Heart Failure - Cardiovascular Disorders - MSD Manual Professional Edition</title>
 
 <!-- Schema.org/Additional markup -->
 
 
 
 
 
 
 
 
 
 
 
 
 
 <!-- Twitter Card data -->
 
 
 
 
 
 <!-- Open Graph data -->
 
 
 
 
 
 
 
 
 
 
<!-- Diagnostic info: TopicMultimediaStructuredData - Topic Resources string is null or empty. --> 
 
 
<!-- Google Tag Manager --> <script></script> <!-- End Google Tag Manager -->
 <script type="text/javascript">
 // Way froward settings. Strongly typed for Typescript code.
 // Typescript definition file is in \src\Foundation\Presentation\code\Scripts\typings\Settings.d.ts
 MManual = window.MManual || {};
 MManual.Foundation = MManual.Foundation || {};
 MManual.Feature = MManual.Feature || {};
 MManual.Foundation.Logging = {
 Level : "WARN"
 }
 MManual.Foundation.Context = {
 Language: {
 Name: "en",
 Code: "en"
 },
 Edition: "Professional"
 }
 MManual.Foundation.Context.Item = {}
 
 MManual.Foundation.Context.Item.SitecoreId = "8421724d-323b-4c1e-a65f-97616ef1e639";
 MManual.Foundation.Context.Item.MediaId = "";
 MManual.Foundation.Context.Item.VasontId = "v31269779";
 MManual.Foundation.Context.Item.TemplateId = "9fe4ab09-1603-40e4-91f9-0ac01a474c58";
 
 
 MManual.Foundation.Context.Chapter = {
 SitecoreId : "350315d7-ed2f-4b6e-a47e-d06601578dca",
 VasontId : "v935838"
 }
 MManual.Foundation.Context.Section = {
 SitecoreId : "ee8ab93f-6fdb-4525-b9c2-55a87a4f1a0c",
 VasontId : "v878834"
 }
 
 MManual.Foundation.TemplateIds = {
 Topic : "9fe4ab09-1603-40e4-91f9-0ac01a474c58"
 }
 MManual.deferredScripts = [];
 // Below settings are obsolete. Please use MManual.Foundation.Context
 //////////////////
 // OBSOLETE START
 ///////////////////
 MManual.settings = MManual.settings || {};
 MManual.settings.edition = "Professional";
 MManual.settings.language = "en";
 MManual.settings.languageCode = "en";
 MManual.settings.displayDateFormat = "dd/MM/yy";
 MManual.settings.dateFormat = "dd/MM/yy";
 MManual.settings.loadLocationsGlobal = true;
 MManual.settings.LexicompEnabled = false;
 MManual.settings.topic = MManual.settings.topic || {};
 MManual.settings.topic.getTopicsForResourceUrl = "/Redesign/Topic/GetTopicsForResource";
 MManual.settings.topic.getTopicHelpfulUrl = "/Redesign/Topic/GetTopicHelpful";
 MManual.settings.topic.wasThisTopicHelpfulUrl = "/Redesign/Topic/WasThisTopicHelpful";
 MManual.settings.topic.getTableBodyUrl = "/Redesign/Topic/GetTableBody";
 MManual.settings.socialMedia = MManual.settings.socialMedia || {};
 MManual.settings.socialMedia.enableMultimediaPopupShareButton = true;
 MManual.CommonLetters = ['A', 'B', 'C', 'D', 'E', 'F', 'G', 'H', 'I', 'J', 'K', 'L', 'M', 'N', 'O', 'P', 'Q', 'R', 'S', 'T', 'U', 'V', 'W', 'X', 'Y', 'Z'];
 MManual.CommonNumbers = ['0', '1', '2', '3', '4', '5', '6', '7', '8', '9'];
 MManual.Context = MManual.settings;
 MManual.Context.Item = MManual.Foundation.Context.Item;
 /////////////////
 // OBSOLETE END
 /////////////////
 </script>
 <script src="./Content/Scripts/Redesign/Lib/jquery-3.5.1.min.js" type="text/javascript"></script>
 <script src="./Content/Scripts/Redesign/Lib/jquery-ui-1.13.1.custom/jquery-ui.min.js" type="text/javascript"></script>
 <script src="./Content/Scripts/Foundation/Presentation/Library/Knockout/knockout-3.5.1.js" type="text/javascript"></script>
 <script src="./Content/Scripts/Redesign/Lib/hammer.2.0.7.min.js" type="text/javascript"></script>
 <script src="./Content/Scripts/Redesign/Lib/polyfills/es5-shim.4.5.13.min.js" type="text/javascript"></script>
 <script src="./Content/Scripts/Redesign/Lib/polyfills/es6-shim.0.35.4.min.js" type="text/javascript"></script>
 <script src="./Content/Scripts/Redesign/Lib/slick-1.8.0/slick.1.8.0.min.js" type="text/javascript"></script>
<!--[if (gte IE 9)|!(IE)]><!-->
<script src="./bundles/redesign/libsjsv4.1.2.2-13178e13ca.js?v=9oeWsccS0AXvU_mpLneFQpk81D2qyviYAadBAspEdRc1"></script>
<!--<![endif]-->
<!--[if lt IE 9]>
 <script src="/bundles/redesign/ie8libsjsv4.1.2.2-13178e13ca.js?v=NYMKNIKPtdByxJkp3-a4OoxrVMsYmUh3Th334huO0BY1"></script>
<![endif]-->
<!-- Add custom class to categorize all cookies as functional. -->
<script src='./bundles/redesign/mmanualjsv4.1.2.2-13178e13ca.js?v=qZy1l8ugVchOqoSbrCHnQvB_O3jXnpspHrGZgwDHF0I1' class='optanon-category-C0002'></script>
<script defer="" src='./bundles/redesign/mmanualTopicjsv4.1.2.2-13178e13ca.js?v=kSA_yN8XuMyhoVC1QLzYxWJE66uhmC-mSc_-tgT27II1' class='optanon-category-C0002'></script>
<script defer="" src='./bundles/redesign/mmanualTopicResourceSearchjsv4.1.2.2-13178e13ca.js?v=iHsFLQRu7O1_jYYodP5cLz5m6_oggwQ97PNvPDyRMrw1' class='optanon-category-C0002'></script>
<!--Region information -->
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<link rel="preload" href="/Content/Fonts/Redesign/oldrambla/Rambla-Latin-webfont.woff2" as="font" type="font/woff2" crossorigin="anonymous">
<link rel="preload" href="/Content/Fonts/Redesign/OpenSans/OpenSans-700-Bold.woff2" as="font" type="font/woff2" crossorigin="anonymous">
<link rel="preload" href="/Content/Fonts/Redesign/OpenSans/OpenSans-700-Bold-Italic.woff2" as="font" type="font/woff2" crossorigin="anonymous">
<link rel="preload" href="/Content/Fonts/Redesign/OpenSans/OpenSans-400-Regular.woff2" as="font" type="font/woff2" crossorigin="anonymous">
<link rel="preload" href="/Content/Fonts/Redesign/OpenSans/OpenSans-400-Regular-Italic.woff2" as="font" type="font/woff2" crossorigin="anonymous">
<link rel="preload" href="/Content/Fonts/Redesign/OpenSans/OpenSans-300-Light.woff2" as="font" type="font/woff2" crossorigin="anonymous">
<link rel="preload" href="/Content/Fonts/Redesign/OpenSans/OpenSans-600-SemiBold.woff2" as="font" type="font/woff2" crossorigin="anonymous">
<link href="./bundles/redesign/mmanualcssv4.1.2.2-13178e13ca.css?v=RUczVKOp43QqHlIomZoV4XMWus4DZWBAeuESVt-1iCc1" rel="stylesheet" type="text/css" media="screen">
<link href="./bundles/redesign/jqueryuicssv4.1.2.2-13178e13ca.css?v=3k6hV5TZDiil7_Jv0lADrVVLB9hJfoX2PenhijDq_d81" rel="stylesheet" type="text/css" media="screen">
 <link href="./bundles/redesign/mmanualprofessionalcssv4.1.2.2-13178e13ca.css?v=mbUz3b7WGmUBumHpYEaEcWfHb1bxVAgvrA5uGMAlaJ81" rel="stylesheet" type="text/css">
<!--[if lt IE 9]><link href="/bundles/redesign/ie8cssv4.1.2.2-13178e13ca.css?v=" rel="stylesheet"/>
<![endif]-->
<link href="./bundles/redesign/mmanualcssprintv4.1.2.2-13178e13ca.css?v=2xJ7o27xwBLBtbGx65XzwLYcjgNEMec7qcBRi3GYAM01" rel="stylesheet" type="text/css" media="print">
<link href="./bundles/redesign/mmanualcsshybridv4.1.2.2-13178e13ca.css?v=LCUeOfwqiGi437ffhbWXxV6YW74rb9NUl93CESRStCs1" rel="stylesheet" type="text/css" media="hybrid">
<!--[if lt IE 9]>
 <script src="//html5shiv.googlecode.com/svn/trunk/html5.js"></script>
<![endif]-->
<script type="text/javascript">
 function msieversion() {
 var ua = window.navigator.userAgent;
 var msie = ua.indexOf("MSIE ");
 if (msie > 0 || !!navigator.userAgent.match(/Trident.*rv\:11\./) || msie == NaN)
 var test = $('li.no-children');
 test.addClass("noSpace");
 return false;
 };
 //msieversion();
</script>
<div style="display: none">
 <div class="confirmationpopup__container" id="access-confirmation-popup" style="z-index: 10000;">
 <div>
 <div>
 <div>
 <div class="confirmationpopup__container">
 <span class="confirmationpopup__logo"></span>
 <div class="confirmationpopup__title">
 <span class="confirmationpopup__text">MSD Manual</span>
 </div>
 <div class="confirmationpopup__description">
 <p>Please confirm that you are a health care professional</p>
 </div>
 <div class="confirmationpopup__answer">
 <a class="confirmationpopup__button confirmationpopup__button--yes" role="button">Yes</a>
 <a class="confirmationpopup__button confirmationpopup__button--no" role="button">No</a>
 </div>
 </div>
 </div>
 </div>
 </div>
 </div>
</div>
<div style="display: none">
 <div class="confirmationpopup__container" id="external-link-confirmation-popup" style="z-index: 10000;">
 <div>
 <div>
 <div>
 <div class="confirmationpopup__container">
 <span class="confirmationpopup__logo"></span>
 <div class="confirmationpopup__title">
 <span class="confirmationpopup__text">Leave this Site?</span>
 </div>
 <div class="confirmationpopup__description">
 <p>The link you have selected will take you to a third-party website. We do not control or have responsibility for the content of any third-party site.</p>
 </div>
 <div class="confirmationpopup__answer">
 <a class="confirmationpopup__button confirmationpopup__button--yes" role="button">Continue </a>
 <a class="confirmationpopup__button confirmationpopup__button--no" role="button">Cancel</a>
 </div>
 </div>
 </div>
 </div>
 </div>
 </div>
</div>
 <script> 
 var externalUrls = JSON.parse(atob('["www.cdc.gov/mmwr/preview/mmwrhtml/rr58e324a1.htm","www.cdc.gov/mmwr/preview/mmwrhtml/rr6403a1.htm","www.cdc.gov/vaccines/vpd/hepb/hcp/faqs-hcp-pediarix.html","cid.oxfordjournals.org/content/53/7/e25.full.pdf html?sid=67183860-0d8a-4d54-9d57-fd12d5682421","www.nature.com/articles/s41467-022-32936-3","pubmed.ncbi.nlm.nih.gov/35772465","pubmed.ncbi.nlm.nih.gov/31515408","www.ncbi.nlm.nih.gov/pmc/articles/PMC4028378","www.drugs-porphyria.org","porphyriafoundation.org/drugdatabase","aasldv2019stg.aasld.org/sites/default/files/2019-06/NAFLD Guidance 2018.pdf","aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.31060","academic.oup.com/cid/article/58/1/e1/374007","www.cdc.gov/hepatitis/hav/havfaq.htm","journals.lww.com/ajg/Fulltext/2018/02000/ACG_Clinical_Guideline__Alcoholic_Liver_Disease.9.aspx","www.cdc.gov/mmwr/preview/mmwrhtml/rr6007a1.htm","jama.jamanetwork.com/article.aspx?articleid=2492881","www.nhlbi.nih.gov/health-pro/guidelines/current/cardiovascular-health-pediatric-guidelines","gi.org/guideline/genetic-testing-and-management-of-hereditary-gastrointestinal-cancer-syndromes","rheumatology.oxfordjournals.org/content/42/2/235.full.pdf","onlinelibrary.wiley.com/doi/10.1002/14651858.CD003448.pub4/abstract?systemMessage=Wiley Online Library will be unavailable on Saturday 17th December 2016 at 09:00 GMT/ 04:00 EST/ 17:00 SGT for 4hrs due to essential maintenance.Apologies for the inconvenience","cid.oxfordjournals.org/content/early/2016/11/03/cid.ciw670.full","www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm","onlinelibrary.wiley.com/doi/10.1111/apt.13148/abstract","onlinelibrary.wiley.com/doi/10.1359/jbmr.06s204/abstract","onlinelibrary.wiley.com/doi/10.1002/jbmr.438/abstract","journals.lww.com/infectdis/Fulltext/2013/05000/New_Guidelines_for_Antimicrobial_Prophylaxis_in.10.aspx","jama.jamanetwork.com/article.aspx?articleid=1487498","cid.oxfordjournals.org/content/46/12/1801.full","www.cdc.gov/mmwr/volumes/67/wr/mm6703a5.htm","www.cdc.gov/mmwr/volumes/68/wr/mm6832a3.htm","www.onlinejacc.org/content/64/22/e77","jamanetwork.com/journals/jamasurgery/fullarticle/2623725","www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html#t-01","www.cdc.gov/mmwr/preview/mmwrhtml/rr5911a1.htm","www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm","www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html","www.cdc.gov/mmwr/volumes/65/rr/rr6503a1.htm","www.onlinejacc.org/content/56/22/1864","www.idsociety.org/practice-guideline/hap_vap","academic.oup.com/cid/article-lookup/doi/10.1086/649858","acp.silverchair-cdn.com/acp/content_public/journal/aim/937814/m183600ff3_panel_2.jpeg?Expires=1556744998&amp;Signature=Oc7aO8PzGrh4tsbJzhWwSTvws~WHIkN~BaNqycHCh1TDufduqpbjgojduPU-8q5Owv2tym0x3HekrEXjegtUiZ2C15Qag5cNuhdxGu84JMb5nLmefg~ofSQfhTAdRWr9ECrJt4a1nu0Rl2crQwlTdDcL4Q8k9MGLgeg6yqGHzJGmlul2E8fEWxiP1ivlR9GypBYLjQ-B3eUH4hi-SYVCDfitv2zjW01hFzUlZM6OSXb5yEGThsimV8yQSCxcSLwaaY~CnZZ96lrcrr87nkPmtyvM9iPUUs-ix3Be5lXTIDWuIRrY3xmWXTnpNu7fxROSemZYm5ESTXbpGdJH6gMyuA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA","www.cdc.gov/mmwr/preview/mmwrhtml/mm6203a3.htm","www.cdc.gov/mmwr/volumes/68/wr/mm6832a3.htm","www.ncbi.nlm.nih.gov/pubmed?term=Crit Care Med[Jour] AND 42[volume] AND 1157[page] AND 2014[pdat] AND Karvellas CJ[first author] AND Outcomes and complications of intracranial pressure monitoring in acute liver failure&amp;TransSchema=title&amp;cmd=detailssearch","www.ncbi.nlm.nih.gov/pubmed?term=\"Hepatology (Baltimore, Md.)\"[Jour] AND 66[volume] AND 1219[page] AND 2017[pdat] AND Albillos A[author] AND Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis. &amp;TransSchema=title&amp;cmd=detailssearch","fascrs.org/ascrs/media/files/downloads/Clinical Practice Guidelines/the-american-society-of-colon-practical-guideline-sinus-pilonidalis.pdf","fascrs.org/ascrs/media/files/downloads/Clinical Practice Guidelines/practice_parameters_for_the_management_of_hemorrhoids.pdf\"","www.cdc.gov/mmwr/preview/mmwrhtml/mm5803a4.htm","www.cdc.gov/mmwr/volumes/67/wr/mm6722a5.htm","pubmed.ncbi.nlm.nih.gov/21956720-evidence-report-genetic-and-metabolic-testing-on-children-with-global-developmental-delay-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology-society?from_term=\"Neurology\"[Jour] AND 2011[pdat]&amp;from_pos=7","www.nal.usda.gov/fnic/vitamins-and-minerals","www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management","www.willseye.org/doctor/melvin-roat-md-facs","faculty.mdanderson.org/profiles/pedro_ramirez.html","pharmacy.ucsf.edu/shalini-lynch","weillcornell.org/jwbarnhill","profiles.stanford.edu/david-spiegel","www.umc.edu/doctors/Huang_Juebin","www.chop.edu/doctors/moldenhauer-julie-s","www.urmc.rochester.edu/people/20996734-stephen-brian-sulkes","podiatry.temple.edu/kendrick-whitney","www.med.upenn.edu/apps/faculty/index.php/g275/p8178541","www.urmc.rochester.edu/people/21136627-ronald-rabinowitz","psychiatry.ubc.ca/person/rosemary-basson","profiles.utsouthwestern.edu/profile/48082/ravindra-sarode.html","sop.washington.edu/people/brian-werth","pharmacy.ucsd.edu/faculty/le","www.chop.edu/doctors/calabria-andrew-c","medicine.uiowa.edu/psychiatry/profile/william-coryell","www.chop.edu/doctors/mehta-jay","www.adelphi.edu/faculty/profiles/profile.php?PID=0649","www.ot.wustl.edu/about/our-people/peggy-barco-8","www.urmc.rochester.edu/people/21411717-jimena-cubillos","www.mlanet.org/resources/userguide.html","www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-vaccine-fact-sheet#how-effective-are-hpv-vaccines","www.ncbi.nlm.nih.gov/books/NBK25349","www.nichd.nih.gov/sites/default/files/2018-09/PRGLAC_Report.pdf","academic.oup.com/cid/article/45/7/941/544359","academic.oup.com/cid/article/55/10/e86/321183","aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.29800","aasldv2019stg.aasld.org/sites/default/files/2019-06/NAFLD Guidance 2018.pdf","www.cdc.gov/hepatitis/hav/havfaq.htm","www.nejm.org/doi/10.1056/NEJMoa1613512?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub  0www.ncbi.nlm.nih.gov","www.ncbi.nlm.nih.gov/pmc/articles/PMC5848239","pubmed.ncbi.nlm.nih.gov/29260225","aasldv2019stg.aasld.org/sites/default/files/2019-06/NAFLD Guidance 2018.pdf","www.cdc.gov/hepatitis/hav/havfaq.htm","aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.29800","jamanetwork.com/article.aspx?articleid=1487498","www.nejm.org/doi/10.1056/NEJMoa1613512?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub  0www.ncbi.nlm.nih.gov","circ.ahajournals.org/content/132/15/1435.long","www.porphyriafoundation.com","porphyriafoundation.org/for-healthcare-professionals/drug-safety","www.porphyria-europe.com","www.drugs-porphyria.org","profiles.stanford.edu/judith-prochaska","circ.ahajournals.org/content/132/15/1435.long","aasld.org/publications/practice-guidelines","www.uspreventiveservicestaskforce.org/Page/Topic/recommendation-summary/hepatitis-c-screening","aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.31065","www.ncbi.nlm.nih.gov/pubmed/22972059","aasldv2019stg.aasld.org/sites/default/files/2019-06/NAFLD Guidance 2018.pdf","academic.oup.com/cid/article/53/7/e25/424286","www.idsociety.org/practice-guideline/community-acquired-pneumonia-cap-in-adults","www.idsociety.org/practice-guideline/hap_vap","www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html","porphyriafoundation.org","www.ncbi.nlm.nih.gov/pmc/articles/PMC4695986","www.lajh.org/about/the-jewish-home-team/meet-our-clinicians","www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html","www.ncbi.nlm.nih.gov/pmc/articles/PMC7431966","www.the-scientist.com/news-opinion/vector-based-vaccines-come-to-the-fore-in-the-covid-19-pandemic-67915","www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext","www.med.upenn.edu/apps/faculty/index.php/g275/p8841440","www.cdc.gov/mmwr/volumes/70/rr/rr7001a1.htm","www.essentialaccessibility.com/merck","www.menopause.org/docs/default-source/2017/nams-2017-hormone-therapy-position-statement.pdf","www.ncbi.nlm.nih.gov/pmc/articles/PMC4028378","www.nejm.org/doi/10.1056/NEJMoa2112435?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub  0pubmed","www.ajog.org/article/S0002-9378(21)00963-7/fulltext","www.ajog.org/article/S0002-9378(20)30861-9/fulltext","ascopubs.org/doi/full/10.1200/JCO.21.00006","www.nejm.org/doi/10.1056/NEJMoa2112435?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub  0pubmed","www.ajog.org/article/S0002-9378(21)00963-7/fulltext","www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30020-8/fulltext","ascopubs.org/doi/full/10.1200/JCO.2014.58.3401?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub  0pubmed","ascopubs.org/doi/full/10.1200/JCO.2017.76.5966?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub  0pubmed","www.ajog.org/article/S0002-9378(20)30861-9/fulltext","www.nejm.org/doi/full/10.1056/NEJMoa1910962?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub  0pubmed","jamanetwork.com/journals/jamaoncology/fullarticle/2773114","ascopubs.org/doi/full/10.1200/JCO.21.00006","pubmed.ncbi.nlm.nih.gov/36107786","pubmed.ncbi.nlm.nih.gov/30304427","www.ncbi.nlm.nih.gov/pmc/articles/PMC5958910","www.ahajournals.org/doi/10.1161/HYP.0000000000000084","pubmed.ncbi.nlm.nih.gov/27195814","pubmed.ncbi.nlm.nih.gov/36130612","www.ncbi.nlm.nih.gov/pmc/articles/PMC9940918","pubmed.ncbi.nlm.nih.gov/36351458","pubmed.ncbi.nlm.nih.gov/36041474","pubmed.ncbi.nlm.nih.gov/29608107","pubmed.ncbi.nlm.nih.gov/35316839","pubmed.ncbi.nlm.nih.gov/36148880","pubmed.ncbi.nlm.nih.gov/37295445","www.ncbi.nlm.nih.gov/pmc/articles/PMC7652033","www.nejm.org/doi/10.1056/NEJMoa2032183?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub  0pubmed","www.ahajournals.org/doi/full/10.1161/CIR.0000000000000678?rfr_dat=cr_pub  0pubmed&url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org","diabetesjournals.org/care/article/42/1/126/36330/Racial-and-Ethnic-Differences-in-Anthropometric","agsjournals.onlinelibrary.wiley.com/doi/abs","www.ncbi.nlm.nih.gov/pubmed/31515408","opendata.ncats.nih.gov/covid19/variant/activity","opendata.ncats.nih.gov/variant/activity","diabetesjournals.org/care/article/41/12/2669/36544/Management-of-Hyperglycemia-in-Type-2-Diabetes","pubmed.ncbi.nlm.nih.gov/35772465","pubmed.ncbi.nlm.nih.gov/34004177","pubmed.ncbi.nlm.nih.gov/35973577","www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30925-9/fulltext","pubmed.ncbi.nlm.nih.gov/33349658","pubmed.ncbi.nlm.nih.gov/35834240","pubmed.ncbi.nlm.nih.gov/38319329","www.ncbi.nlm.nih.gov/pmc/articles/PMC10752259","pubmed.ncbi.nlm.nih.gov/35449407","pubmed.ncbi.nlm.nih.gov/19502645","pubmed.ncbi.nlm.nih.gov/35483753","pubmed.ncbi.nlm.nih.gov/3404868"]'));
 $(document).ready(function () {
 $("a").click(function() {
 var href = $(this).attr('href');
 if (MManual.Foundation.Url.IsAbsoluteUrl(href)) {
 var hrefWithoutProtocol = MManual.Foundation.Url.RemoveProtocol(href);
 var match = externalUrls.some(function(url) {
 return url.length > 0 && hrefWithoutProtocol.startsWith(url);
 });
 if (match) {
 externalLinkConfirmation.showConfirmationModal(href);
 } else {
 return true;
 }
 } else {
 return true;
 }
 return false;
 });
 });
 </script>
 <!-- AddToAny script remove-->
<script></script>
 
<script type="text/html" id="audio-player-template">
 <div class="multimedia multimedia--withdescription" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__audio hide-on-print">
 <div class="multimedia__audio--wrapper">
 <audio>
 <source data-bind="attr: { src: AudioUrl, type: MimeType }" />
 </audio>
 </div>
 </div>
 <div class="multimedia__description">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 <div class="multimedia__description--wrapper">
 <!-- ko if: $data.Description -->
 <div class="multimedia__description--content">
 <p data-bind="html: Description"></p>
 </div>
 <!-- /ko -->
 <!-- ko if: $data.Credits -->
 <div class="multimedia__description--credits">
 <p data-bind="html: Credits"></p>
 </div>
 <!-- /ko -->
 </div>
 <!-- ko if: loadLocations -->
 <!-- ko ifnot: topicsWithResource().length == 0 -->
 <div id="multimedia__locations" class="multimedia__description--locations">
 <div class="multimedia__description--readmore">In these topics</div>
 <!-- ko foreach: topicsWithResource-->
 <a class="multimedia__description--location" data-bind="attr: { href: PublicUrl }, html: Title"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
</script>
<script type="text/html" id="inlinemedia-audio-template">
 <!-- ko if: isSideline-->
 <div class="inlinebox inlinebox--right inlinebox--clickable" data-bind="attr: {id: ItemId}, css: {'inlinebox--right': !IsInCarousel(), 'inlinebox--full': IsInCarousel}">
 <div class="inlinebox__wrapper">
 <!-- ko ifnot: IsInCarousel-->
 <div class="inlinebox__header">Audio</div>
 <!-- /ko -->
 <div class="inlinebox__content">
 <div class="multimedia__link" data-bind="component: { name: 'multimedia-link-text', params: multimediaLinkModel }"></div>
 <div class="inlinebox__button">
 <img loading="lazy" alt="icon" data-bind="attr: {src: ThumbnailUrl}">
 </div>
 </div>
 </div>
 </div>
 <!-- /ko -->
 <!-- ko if: isInline -->
 <div data-bind="css: componentClasses(), attr: {id: ItemId}">
 <div class="inlinemedia__wrapper">
 <div class="inlinemedia__header">
 <div class="inlinemedia__title" data-bind="html: Title"></div>
 </div>
 <div class="inlinemedia__content">
 <audio>
 <source data-bind="attr: { src: AudioUrl, type: MimeType }" />
 </audio>
 <!-- ko if: detailsAvailable -->
 <div class="inlinemedia__more">
 <div class="inlinemedia__action inlinemedia__action--show" data-bind="event: {click: toggleDetailsFunction, keypress: toggleDetailsFunction}">
 <i class="inlinemedia__eye"></i>
 <span class="inlinemedia__details hide" role="button" tabindex="0">
 Show Details
 </span>
 <span class="inlinemedia__details show" role="button" tabindex="0">
 Hide Details
 </span>
 <div class="inlinemedia__information" data-bind="html: Description"></div>
 <div class="inlinemedia__credits" data-bind="html: Credits"></div>
 </div>
 </div>
 <!-- /ko -->
 </div>
 </div>
 </div>
 <!-- /ko -->
 <!-- ko if: isText -->
 <div class="multimedia__link" data-bind="component: { name: multimediaLinkComponentName, params: multimediaLinkModel }"></div>
 <!-- /ko -->
</script>
<script type="text/html" id="biodigital-player-template">
 <div class="multimedia" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__iframe">
 <div class="multimedia__iframe--spacer"></div>
 <div class="multimedia__iframe--wrapper">
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="no" frameBorder="0" data-bind="attr: { src: IframeSrcComputed, title: Title }, iOSresizeIframeToParent : attachResizeCallback, swipe: {next: parentContext.showNext, prev: parentContext.showPrev}" sandbox="allow-modals allow-scripts allow-same-origin allow-forms allow-popups allow-top-navigation"></iframe>
 </div>
 <div class="multimedia__iframe--spacer"></div>
 </div>
 <div class="multimedia__description" data-bind="getDivRef : $parent.descriptionDivRef">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 <!-- ko ifnot: parentContext.displaySingle -->
 <div class="multimedia__pager hide-on-print">
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showFirst">«</a>
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showPrev">‹</a>
 <span class="multimedia__pager--number" data-bind="text: $parent.activeEntry().index + 1"></span>/<span class="multimedia__pager--number" data-bind="text: $parent.activeList().length"></span>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showNext">›</a>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showLast">»</a>
 </div>
 <!-- /ko -->
 <!-- ko if: loadLocations -->
 <!-- ko ifnot: topicsWithResource().length == 0 -->
 <div id="multimedia__locations" class="multimedia__description--locations">
 <div class="multimedia__description--readmore">In these topics</div>
 <!-- ko foreach: topicsWithResource-->
 <a class="multimedia__description--location" data-bind="attr: { href: PublicUrl }, html: Title"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
</script><script type="text/html" id="inlinemedia-biodigital-template">
 <!-- ko ifnot: isText-->
 <div data-bind="css: componentClasses()">
 <div class="inlinemedia__wrapper">
 <div class="inlinemedia__header">
 <div class="inlinemedia__title" data-bind="html: Title"></div>
 <!-- ko if: isSideline() && !IsInCarousel() -->
 <div class="inlinemedia__open hide-on-print">
 <i class="inlinemedia__icon--open"></i>
 </div>
 <!-- /ko -->
 </div>
 <div class="inlinemedia__content">
 <!-- ko if: isSideline -->
 <figure class="box__figure">
 <img oncontextmenu="return false;" loading="lazy" class="box__picture" data-bind="attr: {src: ThumbnailUrl, alt: Title, width:ImageWidth, height:ImageHeight}" />
 <div class="box__action"></div>
 <div class="box__label">3D MODEL</div>
 </figure>
 <!-- /ko -->
 <!-- ko if: isInline -->
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="no" seamless="seamless" frameBorder="0" data-bind="attr: { src: IframeSrc, title: Title }"></iframe>
 <!-- /ko -->
 </div>
 <!-- ko ifnot: isInline -->
 <div class="multimedia__link" data-bind="component: { name: multimediaLinkComponentName, params: multimediaLinkModel }"></div>
 <!-- /ko -->
 </div>
 </div>
 <!-- /ko -->
 <!-- ko if: isText -->
 <div class="multimedia__link" data-bind="component: { name: multimediaLinkComponentName, params: multimediaLinkModel }"></div>
 <!-- /ko -->
</script>
 
<script type="text/html" id="image-player-template">
 <div class="multimedia multimedia--withdescription" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__image" data-bind="css: zoomClass">
 <div class="multimedia__image--spacer hide-on-print"></div>
 <div class="multimedia__image--wrapper">
 <img oncontextmenu="return false;" loading="lazy" data-bind="attr: { src: ImageUrl, alt: Alt}, getImageDimensions: imageDimensions, pinchZoom: { pinchZoomActive: pinchZoomActive, isZoomed: isZoomed}">
 </div>
 <!-- ko if: zoomEnabled -->
 
 <!-- /ko -->
 <div class="multimedia__image--spacer hide-on-print"></div>
 </div>
 <div class="multimedia__description">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 <!-- ko ifnot: parentContext.displaySingle -->
 <div class="multimedia__pager hide-on-print">
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showFirst">«</a>
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showPrev">‹</a>
 <span class="multimedia__pager--number" data-bind="text: $parent.activeEntry().index + 1"></span>/<span class="multimedia__pager--number" data-bind="text: $parent.activeList().length"></span>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showNext">›</a>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showLast">»</a>
 </div>
 <!-- /ko -->
 <div class="multimedia__description--wrapper">
 <!-- ko if: $data.Description -->
 <div class="multimedia__description--content" data-bind="html: Description"> </div>
 <!-- /ko -->
 <!-- ko if: $data.Credits -->
 <div class="multimedia__description--credits" data-bind="html: Credits"> </div>
 <!-- /ko -->
 </div>
 <!-- ko if: loadLocations -->
 <!-- ko ifnot: topicsWithResource().length == 0 -->
 <div id="multimedia__locations" class="multimedia__description--locations" data-bind="modalLocations: topicsWithResource().length">
 <div class="multimedia__description--readmore">In these topics</div>
 <!-- ko foreach: topicsWithResource-->
 <a class="multimedia__description--location" data-bind="attr: { href: PublicUrl }, html: Title"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
</script>
<script type="text/javascript">
 (function (MManual) {
 var deferredScripts = [];
 
 deferredScripts.push("./bundles/redesign/imageplayerv4.1.2.2-13178e13ca.js?v=sWgoLvG7zFKbYfkOiaTYY5tBk5gefAsRS0qs0ENFdUc1");
 
 MManual.ImagePlayerScripts = deferredScripts;
 }(window.MManual = window.MManual || {}));
</script>
<script type="text/html" id="inlinemedia-photo-template">
 <!-- ko ifnot: isText-->
 <div data-bind="css: componentClasses()">
 <div class="inlinemedia__wrapper">
 <div class="inlinemedia__innerwrapper">
 <div class="inlinemedia__header">
 <div class="inlinemedia__title" data-bind="html: Title"></div>
 <div class="inlinemedia__open hide-on-print">
 <i class="inlinemedia__icon--open"></i>
 </div>
 </div>
 <div class="inlinemedia__content">
 <div class="inlinemedia__image--container">
 <img class="h-nocopy" loading="lazy" oncontextmenu="return false;" data-bind="attr: { src: ThumbnailUrl, alt: Alt, width:ImageWidth, height:ImageHeight }" />
 </div>
 <!-- ko if: isSideline -->
 <div class="inlinemedia__subtitle" data-bind="html: Credits"></div>
 <!-- /ko -->
 </div>
 <div class="multimedia__link" data-bind="component: { name: multimediaLinkComponentName, params: multimediaLinkModel }"></div>
 </div>
 <div class="inlinemedia__content">
 <!-- ko if: isInline() && detailsAvailable() -->
 <div class="inlinemedia__more">
 <div class="inlinemedia__action inlinemedia__action--show" data-bind="event: {click: toggleDetailsFunction, keypress: toggleDetailsFunction}">
 <i class="inlinemedia__eye"></i>
 <span class="inlinemedia__details hide" role="button" tabindex="0">
 Show Details
 </span>
 <span class="inlinemedia__details show" role="button" tabindex="0">
 Hide Details
 </span>
 <div class="inlinemedia__information" data-bind="html: Description"></div>
 <div class="inlinemedia__credits" data-bind="html: Credits"></div>
 </div>
 </div>
 <!-- /ko -->
 </div>
 </div>
 </div>
 <!-- /ko -->
 <!-- ko if: isText -->
 <div class="multimedia__link" data-bind="component: { name: multimediaLinkComponentName, params: multimediaLinkModel }"></div>
 <!-- /ko -->
</script>
<script type="text/html" id="infographic-player-template">
 <div class="multimedia" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__image" data-bind="css: zoomClass">
 <div class="multimedia__image--spacer hide-on-print"></div>
 <div class="multimedia__image--wrapper h-nocopy">
 <img oncontextmenu="return false;" loading="lazy" data-bind="attr: { src: ImageUrl, alt: Title}, getImageDimensions: imageDimensions, pinchZoom: { pinchZoomActive: pinchZoomActive, isZoomed: isZoomed}">
 </div>
 <!-- ko if: zoomEnabled -->
 <div class="multimedia__image--actions hide-on-print">
 <div class="multimedia__image--actionzoom" data-bind="click: toggleZoom"></div>
 </div>
 <!-- /ko -->
 <div class="multimedia__image--spacer hide-on-print"></div>
 </div>
 <div class="multimedia__description">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 <div class="multimedia__description--wrapper">
 <!-- ko if: CitationLink -->
 <div class="multimedia__description--source">
 <span class="multimedia__description--sourcetitle">Source:</span>
 <!-- ko if: CitationText -->
 <a href="#" class="multimedia__description--citation" data-bind="text: CitationText, attr: { href: CitationLink }"></a>
 <!-- /ko -->
 <!-- ko ifnot: CitationText -->
 <a href="#" class="multimedia__description--citation" data-bind="text: CitationLink, attr: { href: CitationLink }"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 </div>
 </div>
 </div>
</script>
<script type="text/html" id="inlinemedia-labtest-template">
 <!-- ko if: isSideline -->
 <div class="inlinebox inlinebox--clickable" data-bind="css: {'inlinebox--right': !IsInCarousel(), 'inlinebox--full': IsInCarousel}">
 <div class="inlinebox__wrapper">
 <!-- ko ifnot: IsInCarousel-->
 <div class="inlinebox__header">Lab Test</div>
 <!-- /ko -->
 <div class="inlinebox__content">
 <div class="multimedia__link" data-bind="component: { name: 'multimedia-link-text', params: multimediaLinkModel }"></div>
 <div class="inlinebox__button">
 <img class="labtest-icon" loading="lazy" alt="icon" data-bind="attr: {src: ThumbnailUrl }" width="55" height="55" />
 </div>
 </div>
 </div>
 </div>
 <!-- /ko -->
 <!-- ko if: isInline -->
 <div data-bind="css: componentClasses()">
 <div class="inlinemedia__wrapper">
 <div class="inlinemedia__header">
 <div class="inlinemedia__title" data-bind="html: Title"></div>
 </div>
 <div class="inlinemedia__content">
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="yes" seamless="seamless" frameBorder="0" data-bind="attr: { src: IframeSrc, title: Title }"></iframe>
 </div>
 </div>
 </div>
 <!-- /ko -->
 <!-- ko if: isText -->
 <div class="multimedia__link" data-bind="component: { name: multimediaLinkComponentName, params: multimediaLinkModel }"></div>
 <!-- /ko -->
</script><script type="text/html" id="labtest-player-template">
 <div class="multimedia" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__iframe">
 <div class="multimedia__iframe--spacer"></div>
 <div class="multimedia__iframe--wrapper h-ios-iframe-scroll">
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="auto" seamless="seamless" frameBorder="0" data-bind="attr: { src: IframeSrcComputed, title: Title }, setIframePrintTarget: setIframePrintTarget" sandbox="allow-modals allow-scripts allow-same-origin allow-forms allow-popups allow-top-navigation"></iframe>
 </div>
 <div class="multimedia__iframe--spacer"></div>
 </div>
 <div class="multimedia__description">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 <!-- ko ifnot: parentContext.displaySingle -->
 <div class="multimedia__pager hide-on-print">
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showFirst">Â«</a>
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showPrev">â€¹</a>
 <span class="multimedia__pager--number" data-bind="text: $parent.activeEntry().index + 1"></span>/<span class="multimedia__pager--number" data-bind="text: $parent.activeList().length"></span>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showNext">â€º</a>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showLast">Â»</a>
 </div>
 <!-- /ko -->
 <!-- ko if: loadLocations -->
 <!-- ko ifnot: topicsWithResource().length == 0 -->
 <div id="multimedia__locations" class="multimedia__description--locations" data-bind="modalLocations: topicsWithResource().length">
 <div class="multimedia__description--readmore">In these topics</div>
 <!-- ko foreach: topicsWithResource-->
 <a class="multimedia__description--location" data-bind="attr: { href: PublicUrl }, html: Title"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
</script>
<script type="text/html" id="mediawidget-labtest-template">
 <!-- ko component: {name: 'multimedia-link-text', params: { item: ko.mapping.fromJS({
 ItemId: ItemId,
 IframeSrc: MediaUrl,
 Title: Title,
 ShareUrlTitle: ShareUrlTitle,
 Description: Description,
 ThumbnailUrl: ThumbnailUrl,
 Credits: Credits,
 MediaType: 'labest',
 MediaNameTranslated: 'Lab Test' ,
 UniqueId: UniqueId
 }),
 linkText: Title,
 showTooltip: false,
 listName: 'LabTestResources' + $parent.key
 } } -->
 <!-- /ko -->
</script>
<script type="text/html" id="mediawidget-labtest-list-template">
 <!-- ko component: {name: 'multimedia-link-text', params: { item: ko.mapping.fromJS({
 ItemId: ItemId,
 IframeSrc: MediaUrl,
 Title: Title,
 ShareUrlTitle: ShareUrlTitle,
 Description: Description,
 ThumbnailUrl: ThumbnailUrl,
 Credits: Credits,
 MediaType: 'labtest',
 MediaNameTranslated: 'Lab Test',
 UniqueId: UniqueId
 }),
 linkText: Title,
 showTooltip: false,
 listName: 'LabTestResources' + $parent.key
 } } -->
 <!-- /ko -->
</script>
<script type="text/html" id="inlinemedia-featuredlink-template">
 <!-- ko ifnot: isText-->
 <!-- ko ifnot: isModal -->
 <a data-bind="attr: {href: IframeSrcComputed, target: Target}">
 <div data-bind="css: componentClasses()">
 <div class="inlinemedia__wrapper">
 <div class="inlinemedia__header">
 <div class="inlinemedia__title" data-bind="html: Title"></div>
 <!-- ko if: isSideline() && !IsInCarousel() -->
 <div class="inlinemedia__open hide-on-print">
 <i class="inlinemedia__icon--open"></i>
 </div>
 <!-- /ko -->
 </div>
 <div class="inlinemedia__content">
 <!-- ko if: isSideline -->
 <figure class="box__figure">
 <img oncontextmenu="return false;" loading="lazy" class="box__picture" data-bind="attr: {src: ThumbnailUrl, alt: Title}" />
 <div class="box__action"></div>
 <div class="box__label" data-bind="text:MediaNameTranslated"></div>
 </figure>
 <!-- /ko -->
 <!-- ko if: isInline -->
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="no" seamless="seamless" frameBorder="0" data-bind="attr: { src: IframeSrcComputed, title: Title }"></iframe>
 <!-- /ko -->
 </div>
 </div>
 </div>
 </a>
 <!-- /ko -->
 <!-- /ko -->
 <!-- ko if: isModal -->
 <div data-bind="css: componentClasses()">
 <div class="inlinemedia__wrapper">
 <div class="inlinemedia__header">
 <div class="inlinemedia__title" data-bind="html: Title"></div>
 <!-- ko if: isSideline() && !IsInCarousel() -->
 <div class="inlinemedia__open hide-on-print">
 <i class="inlinemedia__icon--open"></i>
 </div>
 <!-- /ko -->
 </div>
 <div class="inlinemedia__content">
 <!-- ko if: isSideline -->
 <figure class="box__figure">
 <img oncontextmenu="return false;" loading="lazy" class="box__picture" data-bind="attr: {src: ThumbnailUrl, alt: Title}" />
 <div class="box__action"></div>
 <div class="box__label" data-bind="text:MediaNameTranslated"></div>
 </figure>
 <!-- /ko -->
 <!-- ko if: isInline -->
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="no" seamless="seamless" frameBorder="0" data-bind="attr: { src: IframeSrcComputed, title: Title }"></iframe>
 <!-- /ko -->
 </div>
 <div class="multimedia__link" data-bind="component: { name: multimediaLinkComponentName, params: multimediaLinkModel }"></div>
 </div>
 </div>
 <!-- /ko -->
 <!-- ko if: isText -->
 <div class="multimedia__link" data-bind="component: { name: multimediaLinkComponentName, params: multimediaLinkModel }">
 </div>
 <!-- /ko -->
</script><script type="text/html" id="featuredlink-player-template">
 <div class="multimedia" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__iframe">
 <div class="multimedia__iframe--spacer"></div>
 <div class="multimedia__iframe--wrapper">
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="yes" frameBorder="0" data-bind="attr: { src: IframeSrcComputed, title: Title }, iOSresizeIframeToParent : attachResizeCallback" sandbox="allow-modals allow-scripts allow-same-origin allow-forms allow-popups allow-top-navigation"></iframe>
 </div>
 <div class="multimedia__iframe--spacer"></div>
 </div>
 <div class="multimedia__description" data-bind="getDivRef : $parent.descriptionDivRef">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 </div>
 </div>
</script><script type="text/html" id="iframe-player-template">
 <div class="multimedia" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__iframe">
 <div class="multimedia__iframe--spacer"></div>
 <div class="multimedia__iframe--wrapper">
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="auto" seamless="seamless" frameBorder="0" data-bind="attr: { src: IframeSrcComputed, title: Title }" sandbox="allow-modals allow-scripts allow-same-origin allow-forms allow-popups allow-top-navigation"></iframe>
 </div>
 <div class="multimedia__iframe--spacer"></div>
 </div>
 <div class="multimedia__description">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 <!-- ko ifnot: parentContext.displaySingle -->
 <div class="multimedia__pager hide-on-print">
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showFirst">«</a>
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showPrev">‹</a>
 <span class="multimedia__pager--number" data-bind="text: $parent.activeEntry().index + 1"></span>/<span class="multimedia__pager--number" data-bind="text: $parent.activeList().length"></span>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showNext">›</a>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showLast">»</a>
 </div>
 <!-- /ko -->
 <!-- ko if: loadLocations -->
 <!-- ko ifnot: topicsWithResource().length == 0 -->
 <div id="multimedia__locations" class="multimedia__description--locations">
 <div class="multimedia__description--readmore">In these topics</div>
 <!-- ko foreach: topicsWithResource-->
 <a class="multimedia__description--location" data-bind="attr: { href: PublicUrl }, html: Title"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
</script><script type="text/html" id="multimedia-thumbnail-template">
 <div class="modalcarousel__item" data-bind="event:{click: $parentContext.$parent.navToClick.bind($index()), keypress: $parentContext.$parent.navToClickKeyPress.bind($index())}, css: {'modalcarousel__item--active' : $parentContext.$parent.activeIndex() == $index()}, attr: { title: item.Title}, modalCarousel, css-static: 'modalcarousel__item--' + item.MediaType()" tabindex="0" role="button">
 <div class="modalcarousel__item--wrapper">
 <div class="modalcarousel__item--imagewrapper h-nocopy">
 <img oncontextmenu="return false;" data-bind="lazyload: {src: item.ThumbnailUrl, options: {loadOnlyInViewport: true} , updateTick: $parentContext.$parent.carouselScrollTick}, attr: {alt: item.Title }, scrollIntoView:$parentContext.$parent.activeIndex() == $index()" />
 </div>
 <div class="modalcarousel__item--text" data-bind="html: item.Title"> </div>
 </div>
 <div class="modalcarousel__item--number" data-bind="text: ($index() + 1)"></div>
 </div>
</script>
<script type="text/html" id="text-player-template">
 <div class="multimedia">
 <div class="multimedia__text" data-bind="html: Text"> </div>
 </div>
</script>
<script type="text/html" id="multimedia-link-block-template">
 <i class="inlinemedia__icon--open"
 data-bind="hoverVisible: enableHover, hoverTargetId: '.multimedia__link'"></i>
 <button class="multimedia__link--block" aria-expanded="false" data-bind="shortClick: showPlayer, attr : {'aria-label':'Expand the'+' '+ item.MediaNameTranslated()}"></button>
</script>
<script type="text/html" id="multimedia-link-text-template">
 <a class="multimedia__link--text" role="button" tabindex="0" aria-expanded="false" data-bind="shortClick: showPlayer, html: linkText, css: cssClass"></a>
</script><div class="multimedia__popup l-viewport" data-bind="component: { name: 'multimedia-popup'}">
 <!-- Placeholder for media players. -->
</div>
<script type="text/html" id="multimedia-popup-template">
 <!-- ko if: playerVisible -->
 <div class="modal" role="dialog" tabindex="-1" aria-labelledby="exampleModalLabel">
 <div class="modal--shade" data-bind="click: hidePopup"></div>
 <div class="modaldialog" data-bind=" arrowKeys: {left: showPrev, right: showNext}, css : {'h-expanded' : expanded }">
 <div class="modaldialog__header hide-on-print">
 <div class="modaldialog__header--wrapper">
 <div class="modaldialog__header--title modaldialog__header--element" data-bind="html: popupTitle(), scaleText: popupTitle"></div>
 <div tabindex="0" role="button" class="modaldialog__header--close modaldialog__header--element" data-bind="event: { click: hidePopup, keypress: hidePopupKeyPress }">
 Close
 </div>
 </div>
 </div>
 <div class="modaldialog__content">
 <div class="modaldialog__content--wrapper" data-bind="swipe: {next: showNext, prev: showPrev, canSwipe: canSwipe}">
 <div class="modaldialog__media" data-bind="css :{ 'modaldialog__media--withcarousel': !(displaySingle() || hideCarousel()), 'modaldialog__media--single': displaySingle }">
 <!-- ko ifnot: (displaySingle() || hideMainArrows()) -->
 <div class="modaldialog__media--sidemargin hide-on-print">
 <div class="modaldialog__media--nav modaldialog__media--prev" tabindex="0" role="button" aria-label="Previous" data-bind="event: { click: showPrev, keypress: showPrevKeyPress }">
 <div class="mm-icon" data-bind="css : showPrevClass()"></div>
 </div>
 </div>
 <!-- /ko -->
 <div class="modaldialog__media--wrapper">
 
 <!-- ko component: {name: activeEntry().item.MediaType() + '-player', params: activeEntry} -->
 <!-- /ko -->
 
 </div>
 <!-- ko ifnot: (displaySingle() || hideMainArrows()) -->
 <div class="modaldialog__media--sidemargin hide-on-print">
 <div class="modaldialog__media--nav modaldialog__media--next" tabindex="0" role="button" aria-label="Next" data-bind="event: { click: showNext, keypress: showNextKeyPress }">
 <div class="mm-icon" data-bind="css: showNextClass()"></div>
 </div>
 </div>
 <!-- /ko -->
 </div>
 <!-- ko ifnot: (displaySingle() || hideCarousel()) -->
 <div class="modaldialog__carousel hide-on-print">
 <div class="modaldialog__carousel--sidemargin modaldialog__carousel--prev" tabindex="0" role="button" data-bind="event:{click: carouselShowPrev, keypress:carouselShowPrevKeyPress}, css : { 'modaldialog__carousel--sidemargin--disabled' : isCarouselShowPrevDisabled() } "></div>
 <div class="modaldialog__carousel--wrapper">
 <div class="modalcarousel" data-bind="scrollTick : carouselScrollTick, scroll : carouselIsScrolled ">
 <!-- ko foreach: {data: activeList, as: 'entry'} -->
 <!-- ko template: {name: 'multimedia-thumbnail-template', data: entry} -->
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
 <div class="modaldialog__carousel--sidemargin modaldialog__carousel--next" tabindex="0" role="button" data-bind="event:{click: carouselShowNext, keypress:carouselShowNextKeyPress}, css : { 'modaldialog__carousel--sidemargin--disabled' : isCarouselShowNextDisabled() }"></div>
 </div>
 <!-- /ko -->
 <div class="modaldialog__toolbar hide-on-print">
 <!-- ko ifnot: displaySingle -->
 <div class="modaldialog__pager">
 <a class="modaldialog__pager--nav modaldialog__pager--navfirst" data-bind="click: showFirst">«</a>
 <a class="modaldialog__pager--nav modaldialog__pager--navleft" data-bind="click: showPrev">‹</a>
 <span class="modaldialog__pager--number" data-bind="text: activeEntry().index + 1"></span>/<span class="modaldialog__pager--number" data-bind="text: activeList().length"></span>
 <a class="modaldialog__pager--nav modaldialog__pager--navright" data-bind="click: showNext">›</a>
 <a class="modaldialog__pager--nav modaldialog__pager--navlast" data-bind="click: showLast">»</a>
 </div>
 <!-- /ko -->
 <div class="modaldialog__actions">
 <!-- ko if: detailsAvailable -->
 <div class="modaldialog__action modaldialog__action--description modaldialog__action--description-show" data-bind="click: toggleExpanded">
 <i class="modaldialog__icon--show"></i>
 <span class="modaldialog__action--text">
 Show Details
 </span>
 </div>
 <div class="modaldialog__action modaldialog__action--description modaldialog__action--description-hide" data-bind="click: toggleExpanded">
 <i class="modaldialog__icon--hide"></i>
 <span class="modaldialog__action--text">
 Hide Details
 </span>
 </div>
 <!-- /ko -->
 <!-- ko if: MManual.settings.socialMedia.enableMultimediaPopupShareButton -->
 <div class="modaldialog__action modaldialog__action--share a2a_kit" data-a2a-icon-color="transparent,transparent" data-bind="attr:{'data-a2a-url': shareUrl}">
 <a class="modaldialog__icon--share a2a_dd" href="https://www.addtoany.com/share" data-a2a-icon-color="transparent,transparent" role="button"></a>
 </div>
 <!-- /ko -->
 <div class="modaldialog__action modaldialog__action--print" data-bind="event:{click: printPopupContent, keypress:printPopupContentKeyPress}" tabindex="0" role="button" aria-label="print">
 <div class="modaldialog__icon--print"></div>
 </div>
 </div>
 </div>
 <div class="modaldialog__copyright-print">
 <div class="modaldialog__copyright-print--logo">
<img src="/Content/Images/msd_foot_logo.png" alt="" class="badge msd" loading="lazy" width="240" height="71" />
 </div>
 <div class="modaldialog__copyright-print--text">
 © 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
 </div>
 </div>
 </div>
 </div>
 </div>
 </div>
 <!-- /ko -->
</script>
<script type="text/html" id="podcast-player-template">
 <div class="multimedia multimedia--withdescription" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__audio hide-on-print">
 <div class="multimedia__audio--wrapper">
 <audio>
 <source data-bind="attr: { src: AudioUrl, type: MimeType }" />
 </audio>
 </div>
 </div>
 <div class="multimedia__description">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 <!-- ko ifnot: parentContext.displaySingle -->
 <div class="multimedia__pager hide-on-print">
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showFirst">«</a>
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showPrev">‹</a>
 <span class="multimedia__pager--number" data-bind="text: $parent.activeEntry().index + 1"></span>/<span class="multimedia__pager--number" data-bind="text: $parent.activeList().length"></span>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showNext">›</a>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showLast">»</a>
 </div>
 <!-- /ko -->
 <div class="multimedia__description--wrapper">
 <!-- ko if: $data.Description -->
 <div class="multimedia__description--content">
 <p data-bind="html: Description"></p>
 </div>
 <!-- /ko -->
 <!-- ko if: $data.Credits -->
 <div class="multimedia__description--credits">
 <p data-bind="html: Credits"></p>
 </div>
 <!-- /ko -->
 </div>
 <!-- ko if: loadLocations -->
 <!-- ko ifnot: topicsWithResource().length == 0 -->
 <div id="multimedia__locations" class="multimedia__description--locations" data-bind="modalLocations: topicsWithResource().length">
 <div class="multimedia__description--readmore">In these topics</div>
 <!-- ko foreach: topicsWithResource-->
 <a class="multimedia__description--location" data-bind="attr: { href: PublicUrl }, html: Title"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
</script>
 <script type="text/html" id="quiz-player-template">
 <div class="multimedia" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <h3 class="multimedia__title" data-bind="html: Title"> </h3>
 <!-- /ko -->
 <div class="multimedia__iframe">
 <div class="multimedia__iframe--spacer"></div>
 <div class="multimedia__iframe--wrapper h-ios-iframe-scroll">
 <iframe frameBorder="0" scrolling="auto" data-bind="attr: { src: IframeSrcComputed, title: Title }" sandbox="allow-modals allow-scripts allow-same-origin allow-forms allow-popups allow-top-navigation, swipe: {left: parentContext.showNext, right: parentContext.showPrev}"></iframe>
 </div>
 <div class="multimedia__iframe--spacer"></div>
 </div>
 </div>
</script>
<script type="text/html" id="table-player-template">
 <div class="multimedia" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__table">
 <div class="multimedia__table--wrapper">
 <div data-bind="html: tableBody, stickyHeaderTable: tableBody" class="modaltable"> </div>
 </div>
 </div>
 <div class="multimedia__description">
 <!-- ko if: loadLocations -->
 <!-- ko ifnot: topicsWithResource().length == 0 -->
 <div id="multimedia__locations" class="multimedia__description--locations" data-bind="modalLocations: topicsWithResource().length">
 <div class="multimedia__description--readmore">In these topics</div>
 <!-- ko foreach: topicsWithResource-->
 <a class="multimedia__description--location" data-bind="attr: { href: PublicUrl }, html: Title"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
</script><script type="text/html" id="m-link-text-template">
 <!-- ko if: isModal -->
 <a class="multimedia__link--text" tabindex="0" role="button" data-bind="shortClick: showPlayer, html: linkText, css: cssClass, attr: { title: item.Title }, mlinkToolTip: { thumbnail: item.ThumbnailUrl, title: item.Title, show: showTooltip, target: target }"></a>
 <!-- /ko -->
 <!-- ko ifnot: isModal -->
 <!--ko if: item.MediaType()=='podcast'-->
 <a class="multimedia__link--text" tabindex="0" role="button" data-bind="html: linkText, css: cssClass, attr: { title: item.Title, target: target, href: target=='_blank'? url :'https://www.msdmanuals.com/'+ url }, mlinkToolTip: { thumbnail: item.ThumbnailUrl, title: item.Title, show: showTooltip, target: target, url:url}"></a>
 <!-- /ko -->
 <!--ko ifnot: item.MediaType()=='podcast'-->
 <a class="multimedia__link--text" tabindex="0" role="button" data-bind="html: linkText, css: cssClass, attr: { title: item.Title, target: target, href: 'https://www.msdmanuals.com/'+'/professional/multimedia'+ url }, mlinkToolTip: { thumbnail: item.ThumbnailUrl, title: item.Title, show: showTooltip, target: target, url:'/professional/multimedia'+ url}"></a>
 <!-- /ko -->
 <!-- /ko -->
</script>
<script type="text/html" id="clinicalcalculator-player-template">
 <div class="multimedia" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__iframe">
 <div class="multimedia__iframe--spacer"></div>
 <div class="multimedia__iframe--wrapper h-ios-iframe-scroll">
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="auto" seamless="seamless" frameBorder="0" data-bind="attr: { src: IframeSrcComputed, title: Title }, setIframePrintTarget: setIframePrintTarget" sandbox="allow-modals allow-scripts allow-same-origin allow-forms allow-popups allow-top-navigation"></iframe>
 </div>
 <div class="multimedia__iframe--spacer"></div>
 </div>
 <div class="multimedia__description">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 <!-- ko ifnot: parentContext.displaySingle -->
 <div class="multimedia__pager hide-on-print">
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showFirst">«</a>
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showPrev">‹</a>
 <span class="multimedia__pager--number" data-bind="text: $parent.activeEntry().index + 1"></span>/<span class="multimedia__pager--number" data-bind="text: $parent.activeList().length"></span>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showNext">›</a>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showLast">»</a>
 </div>
 <!-- /ko -->
 <!-- ko if: loadLocations -->
 <!-- ko ifnot: topicsWithResource().length == 0 -->
 <div id="multimedia__locations" class="multimedia__description--locations">
 <div class="multimedia__description--readmore">In these topics</div>
 <!-- ko foreach: topicsWithResource-->
 <a class="multimedia__description--location" data-bind="attr: { href: PublicUrl }, html: Title"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
</script><script type="text/html" id="inlinemedia-calculator-template">
 <!-- ko if: isSideline -->
 <div class="inlinebox inlinebox--clickable" data-bind="css: {'inlinebox--right': !IsInCarousel(), 'inlinebox--full': IsInCarousel}">
 <div class="inlinebox__wrapper">
 <!-- ko ifnot: IsInCarousel-->
 <div class="inlinebox__header">Clinical Calculator:</div>
 <!-- /ko -->
 <div class="inlinebox__content">
 <div class="multimedia__link" data-bind="component: { name: 'multimedia-link-text', params: multimediaLinkModel }"></div>
 <div class="inlinebox__button">
 <img class="labtest-icon" loading="lazy" alt="icon" data-bind="attr: {src: ThumbnailUrl }" width="48" height="48" />
 </div>
 </div>
 </div>
 </div>
 <!-- /ko -->
 <!-- ko if: isInline -->
 <div data-bind="css: componentClasses()">
 <div class="inlinemedia__wrapper">
 <div class="inlinemedia__header">
 <div class="inlinemedia__title" data-bind="html: Title"></div>
 </div>
 <div class="inlinemedia__content">
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="no" seamless="seamless" frameBorder="0" data-bind="attr: { src: IframeSrc, title: Title }"></iframe>
 </div>
 </div>
 </div>
 <!-- /ko -->
 <!-- ko if: isText -->
 <div class="multimedia__link" data-bind="component: { name: multimediaLinkComponentName, params: multimediaLinkModel }"></div>
 <!-- /ko -->
</script>
<script type="text/html" id="video-player-template">
 <div class="multimedia multimedia--withdescription" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__video">
 <div class="multimedia__video--spacer"></div>
 <div class="multimedia__video--wrapper">
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="no" seamless="seamless" frameBorder="0" data-bind="attr: { src: IframeSrcComputed, title: Title }"></iframe>
 <div class="multimedia__video--print" onclick="$(this).hide(); return true;">
 <img loading="lazy" data-bind="attr: { src: ThumbnailUrl, alt: Title }">
 </div>
 </div>
 <div class="multimedia__video--spacer"></div>
 </div>
 <div class="multimedia__description">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 <!-- ko ifnot: parentContext.displaySingle -->
 <div class="multimedia__pager hide-on-print">
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showFirst">Â«</a>
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showPrev">â€¹</a>
 <span class="multimedia__pager--number" data-bind="text: $parent.activeEntry().index + 1"></span>/<span class="multimedia__pager--number" data-bind="text: $parent.activeList().length"></span>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showNext">â€º</a>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showLast">Â»</a>
 </div>
 <!-- /ko -->
 <div class="multimedia__description--wrapper">
 <!-- ko if: $data.Description -->
 <div class="multimedia__description--content" data-bind="html: Description"> </div>
 <!-- /ko -->
 <!-- ko if: $data.Credits -->
 <div class="multimedia__description--credits" data-bind="html: Credits"> </div>
 <!-- /ko -->
 </div>
 <!-- ko if: loadLocations -->
 <!-- ko ifnot: topicsWithResource().length == 0 -->
 <div id="multimedia__locations" class="multimedia__description--locations" data-bind="modalLocations: topicsWithResource().length">
 <div class="multimedia__description--readmore">In these topics</div>
 <!-- ko foreach: topicsWithResource-->
 <a class="multimedia__description--location" data-bind="attr: { href: PublicUrl }, html: Title"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
</script>
<link rel="stylesheet" href="./Content/Styles/fa/fonts/font-awesome.css" type="text/css" media="screen"><link rel="stylesheet" href="./CustomCss/custom_mobile_styles.css"><script type="text/javascript" src="./customscript/videodetail.js?v=j6lqWQ_gaVddXSzk8oBfSqpw8iTwpNFAslFpddsSyrM1"></script><script type="text/javascript" src="./customscript/VideoPath.js?v=j6lqWQ_gaVddXSzk8oBfSqpw8iTwpNFAslFpddsSyrM1"></script><script type="text/javascript" src="./customscript/Appdetail.js?v=j6lqWQ_gaVddXSzk8oBfSqpw8iTwpNFAslFpddsSyrM1"></script><script type="text/javascript" src="./customscript/customscript.js?v=j6lqWQ_gaVddXSzk8oBfSqpw8iTwpNFAslFpddsSyrM1"></script></head>
<body class="professional msd ">
 <a href="/n3wbr@nds" rel="nofollow" style="display:none" arial-hidden="true">honeypot link</a>
 <!-- Google Tag Manager (noscript) --> <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-5MKXR9" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript> <!-- End Google Tag Manager (noscript) --> 
 <div id="testone"> <div class="l-viewport">
 
<input type="hidden" id="currentSitecoreItemId" value="8421724d-323b-4c1e-a65f-97616ef1e639">
<input type="hidden" id="wasThisTopicHelpfulUrl" value="/Custom/Topic/WasThisTopicHelpful">
<input type="hidden" id="getTopicHelpfulUrl" value="/Custom/Topic/GetTopicHelpful">
<input type="hidden" id="languageSwitchUrl" value="/professional/LanguageSwitch">
<input type="hidden" id="resourceServiceUrl" value="/custom/Topic/GetTopicsForResource">
<input type="hidden" id="tableBodyServiceUrl" value="/custom/Topic/GetTableBody">
<input type="hidden" id="getAlphabetUrl" value="/Redesign/Widgets/GetAlphabet">
<input type="hidden" id="landingPageUrl" value="https://www.msdmanuals.com/">
<input type="hidden" id="standaloneMultimediaBaseUrl" value="/professional/multimedia">
<input type="hidden" id="currentEdition" value="Professional">
<input type="hidden" id="currentLanguage" value="en">
<input type="hidden" id="currentLanguage2LetterISO" value="en">
<input type="hidden" id="oldRestrictedBrightcovePlayer" value="3851244774001">
<input type="hidden" id="restrictedBrightcovePlayer" value="5qrY5f1MK_default">
<input type="hidden" id="shareableBrightcovePlayer" value="6CaKiGXJD_default">
<input type="hidden" id="selectLanguageLabel" value="Select Language">
<input type="hidden" id="commonCloseText" value="close">
<input type="hidden" id="readAllText" value="Read All">
 
 <!-- New div groups for LetterSpine and Header has been created
 due to problems with existing styling
 ToDo rewrite whole header and letter spine as one component -->
 <div id="l-group--header-letterpine" class="main-header sticky-header">
 <div class="l-group l-group--header">
 <div id="l-layer--header" class="l-layer l-layer--header" data-header-element-position="static" data-header-element-order="0">
 
 
 
 </div>
 </div>
 </div>
 
 
<script>
 MManual.Feature = MManual.Feature || {};
 MManual.Feature.LetterSpine = MManual.Feature.LetterSpine || {};
 MManual.Feature.LetterSpine.Id = '54ad18e8-ab92-45be-9a26-bf851277ee66';
</script>
 <!-- <div id="l-group--header-letterpine--fixed" class="main-header l-group--header-letterpine-fixed l-group--header-letterpine-fixed--hidden l-group--header-letterpine-fixed--animate">
 <div class="l-group l-group--headerfixed hide-on-print">
 <div class="l-layer l-layer--header l-layer--fixed" data-header-element-position="fixed" data-header-element-order="0">
 
 
 </div>
 </div>
 <div class="l-group l-group--letterspinefixed"></div>
 </div>
 <div class="l-layer l-layer--underskirt">
 </div>-->
 
 
 
 <div class="l-layer l-layer--actiontoolbar">
 
 <div class="l-layer__content">
 <aside class="actiontoolbar hide-on-print">
 <!--<a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--bookmark" onclick="bookmarkPage(this);" href="#"></a>-->
 <a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--download" style="display: none" href="#"></a>
 
 <ul>
 <li class="a2a_kit a2a_kit_size_32 a2a_default_style" data-a2a-icon-color="transparent,transparent">
 <a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--share a2a_dd" href="https://www.addtoany.com/share" rel="noopener" role="button" aria-expanded="false" aria-label="Share in"></a>
 </li>
 <li>
 <a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--print" href="#" onclick="window.print(); MManual.analytics.notifyOpenModal(MManual.analytics.eventPrintAnArticle);" role="button" title="print"></a>
 </li>
 <li class="a2a_kit a2a_kit_size_32 a2a_default_style" data-a2a-icon-color="transparent,transparent">
 <a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--email a2a_button_email" href="#" role="button" title="Mail"></a>
 </li>
 <li class="scroll-to-top">
 <a href="#top" role="button" aria-label="Go To Top" title="Go To Top"><span class="scroll-to-top-img"></span></a>
 </li>
 <li class="scroll-to-bottom">
 <a href="#" role="button" aria-label="Go To Top"><span class="scroll-to-bottom-img"></span></a>
 </li>
 </ul>
 </aside>
 </div>
 
 </div>
 <main id="maincontent" class="l-layer l-layer--main">
 
 <section class="l-layer__content main">
 
 <div class="orderize"></div>
<div class="main__content">
 <div class="topic__wrapper">
 
<script type="text/javascript">
 var resources = [];
 var resourcesIdList = [];
 $.each(resources, function() {
 if (this.MultimediaItem != null) {
 resourcesIdList.push({"itemId": this.MultimediaItem.ItemId, "uniqueId": this.MultimediaItem.UniqueId});
 }
 });
 $('a[href="#also-of-interest-news"],a[href="#also-of-interest-video"],a[href="#also-of-interest-biodigital"],a[href="#also-of-interest-student-stories"]').click(function ()
 {
 window.scrollTo(0, $("#Ph-Item-Lazyloading").offset().top - 230);
 });
</script>
<div class="orderize__candidate" data-orderize="100" itemscope="" itemtype="http://schema.org/MedicalCondition" data-preview-container='.topic__article'>
 <input type="hidden" value="" id="hdnTopicTopTile">
 <div class="autoload-placeholder-top hide-on-print" style="display:none">
 <a class="pre-topic hide-on-print" role="button" aria-hidden="true"></a>
 </div>
 <div class="autoloadSettings" name="Up Next:">
 <a id="autoloadEnable" class="false" role="button" tabindex="-1"></a>
 <a id="autoloadChapter" class="false" role="button" tabindex="-1"></a>
 <a id="autoloadSection" class="false" role="button" tabindex="-1"></a>
 <a id="stopAutoloadChapterCircular" class="false" role="button" tabindex="-1"></a>
 </div>
 <article class="topic__article">
 
<div class="tablebox tablebox--headings">
 <div class="tablebox__cell tablebox__cell--headings">
 <div class="topic__headings">
 <span itemprop="code" itemscope="" itemtype="http://schema.org/MedicalCode">

 </span>
 <div class="topic__header--container">
 <div class="topic__authors topic__authors--container">
 <a id="top" role="button" tabindex="-1"></a>
 <h1 class="topic__header__headermodify--title topic__header__headermodify--title--animate" itemprop="name">
 Drugs for Heart Failure
 </h1>
 <div class="topic__authors-main-cont">
 <p class="topic__authors--description">By </p>
 
 <strong class="topic__label topic__label--author"><a href="./Contributors/fine-nowell.html">Nowell M. Fine</a></strong>
 <p class="topic__authors--description">, MD, SM, Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary</p>
 <div class="topic__revision">
 <div class="topic__authors">
 Reviewed/Revised Sep 2022 
 </div>
 </div>
 </div>
 </div>
 <div class="topic__buttons hide-on-print">
 <div class="topicswitch topic__patient-education topic__patient-education--top" data-icd9="MM1151" tabindex="0" role="link">
 <div class="topic__patient-education--container">
 <div class="topic__patient-education--icon"></div>
 <div class="topic__patient-education--text">
 View PATIENT EDUCATION
 </div>
 </div>
 </div>
 </div>
 </div>
 </div>
 </div>
</div>
 <div class="box topicmenu hide-on-print">
 <div class="topic-section-heading-list">
 <ul>
 <li>
 <a href="#v46183645" class="topicmenu_mobile__paragraph">Classes of Drugs for Heart Failure</a>
 </li>
 <li>
 <a href="#v50500280" class="topicmenu_mobile__paragraph">More Information</a>
 </li>
 </ul>
 </div>
 </div>
<div class="topic__accordion">
 <span id="v31269808" class="anchor"></span><div class="para"> <p>Heart failure (HF) is a syndrome of ventricular dysfunction (see <a href="./{B4986CFA-B2A7-45D5-B89B-470DF0EAD991}.html" data-toggle="tooltip" title="Heart Failure (HF)" data-id="97d068b9-0eda-4bc9-9472-ed2fa564a9af" data-itemid="b4986cfa-b2a7-45d5-b89b-470df0ead991">Heart Failure</a><span id="97d068b9-0eda-4bc9-9472-ed2fa564a9af" class="d-none xref"> <span class="tooltip-container"> <a href="./{B4986CFA-B2A7-45D5-B89B-470DF0EAD991}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Heart Failure (HF) </span> Heart failure (HF) is a syndrome of ventricular dysfunction. Left ventricular (LV) failure causes shortness of breath and fatigue, and right ventricular (RV) failure causes peripheral and abdominal... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/3/2/a/32a-and-32b-chest-xray-patient-bilateral-pleural-effusions.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Heart Failure (HF)" loading="lazy"> </span> </a> </span> </span>).</p></div><span id="v31269810" class="anchor"></span><div class="para"> <p>Drug treatment of heart failure (HF) involves symptom relief with</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v71486494" class="anchor"></span><div class="para"> <p> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183709" data-toggle="tooltip" title="Diuretics" data-id="fe5d6195-f400-44a5-8134-6058be7e2346" data-itemid="8421724d-323b-4c1e-a65f-97616ef1e639">Diuretics</a><span id="fe5d6195-f400-44a5-8134-6058be7e2346" class="d-none xref"> <span class="tooltip-container"> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183709"> <span class="tooltip-content"> <span class="tooltip-heading"> Diuretics </span> Heart failure (HF) is a syndrome of ventricular dysfunction (see Heart Failure). Drug treatment of heart failure (HF) involves symptom relief with Diuretics Nitrates Digoxin <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span></p></div></li><li class="topic__listitem"><span id="v71486497" class="anchor"></span><div class="para"> <p> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183734" data-toggle="tooltip" title="Vasodilators" data-id="bfb6f1b3-d3b9-4e1e-9147-4859259f9612" data-itemid="8421724d-323b-4c1e-a65f-97616ef1e639">Nitrates</a><span id="bfb6f1b3-d3b9-4e1e-9147-4859259f9612" class="d-none xref"> <span class="tooltip-container"> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183734"> <span class="tooltip-content"> <span class="tooltip-heading"> Vasodilators </span> Heart failure (HF) is a syndrome of ventricular dysfunction (see Heart Failure). Drug treatment of heart failure (HF) involves symptom relief with Diuretics Nitrates Digoxin <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span></p></div></li><li class="topic__listitem"><span id="v71486500" class="anchor"></span><div class="para"> <p> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183697" data-toggle="tooltip" title="Digoxin" data-id="3d058a20-24c5-4aac-9597-f2c2880478e0" data-itemid="8421724d-323b-4c1e-a65f-97616ef1e639"><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Digoxin</span></a><span id="3d058a20-24c5-4aac-9597-f2c2880478e0" class="d-none xref"> <span class="tooltip-container"> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183697"> <span class="tooltip-content"> <span class="tooltip-heading"> Digoxin </span> Heart failure (HF) is a syndrome of ventricular dysfunction (see Heart Failure). Drug treatment of heart failure (HF) involves symptom relief with Diuretics Nitrates Digoxin <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span></p></div></li></ul></div><span id="v71486502" class="anchor"></span><div class="para"> <p>Drug treatment for long-term management and improved survival is with</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v71486505" class="anchor"></span><div class="para"> <p> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183657" data-toggle="tooltip" title="Angiotensin converting enzyme (ACE) inhibitors" data-id="10e56804-fff5-4e24-bce5-68fa9af18a39" data-itemid="8421724d-323b-4c1e-a65f-97616ef1e639">Angiotensin converting enzyme (ACE) inhibitors</a><span id="10e56804-fff5-4e24-bce5-68fa9af18a39" class="d-none xref"> <span class="tooltip-container"> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183657"> <span class="tooltip-content"> <span class="tooltip-heading"> Angiotensin converting enzyme (ACE) inhibitors </span> Heart failure (HF) is a syndrome of ventricular dysfunction (see Heart Failure). Drug treatment of heart failure (HF) involves symptom relief with Diuretics Nitrates Digoxin <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span></p></div></li><li class="topic__listitem"><span id="v71486508" class="anchor"></span><div class="para"> <p> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183690" data-toggle="tooltip" title="Beta-blockers" data-id="af62d9b0-2ba2-409b-880b-6fa74fa05238" data-itemid="8421724d-323b-4c1e-a65f-97616ef1e639">Beta-blockers</a><span id="af62d9b0-2ba2-409b-880b-6fa74fa05238" class="d-none xref"> <span class="tooltip-container"> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183690"> <span class="tooltip-content"> <span class="tooltip-heading"> Beta-blockers </span> Heart failure (HF) is a syndrome of ventricular dysfunction (see Heart Failure). Drug treatment of heart failure (HF) involves symptom relief with Diuretics Nitrates Digoxin <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span></p></div></li><li class="topic__listitem"><span id="v71486511" class="anchor"></span><div class="para"> <p> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183648" data-toggle="tooltip" title="Aldosterone antagonists" data-id="1f246a17-fd00-4aee-8e66-c23502c38581" data-itemid="8421724d-323b-4c1e-a65f-97616ef1e639">Aldosterone antagonists</a><span id="1f246a17-fd00-4aee-8e66-c23502c38581" class="d-none xref"> <span class="tooltip-container"> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183648"> <span class="tooltip-content"> <span class="tooltip-heading"> Aldosterone antagonists </span> Heart failure (HF) is a syndrome of ventricular dysfunction (see Heart Failure). Drug treatment of heart failure (HF) involves symptom relief with Diuretics Nitrates Digoxin <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span></p></div></li><li class="topic__listitem"><span id="v71486514" class="anchor"></span><div class="para"> <p> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183668" data-toggle="tooltip" title="Angiotensin II receptor blockers (ARBs)" data-id="d3a0b0ea-b2e6-46dc-bfbd-67bf7ac05816" data-itemid="8421724d-323b-4c1e-a65f-97616ef1e639"><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Angiotensin II</span> receptor blockers (ARBs)</a><span id="d3a0b0ea-b2e6-46dc-bfbd-67bf7ac05816" class="d-none xref"> <span class="tooltip-container"> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183668"> <span class="tooltip-content"> <span class="tooltip-heading"> Angiotensin II receptor blockers (ARBs) </span> Heart failure (HF) is a syndrome of ventricular dysfunction (see Heart Failure). Drug treatment of heart failure (HF) involves symptom relief with Diuretics Nitrates Digoxin <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span></p></div></li><li class="topic__listitem"><span id="v71486517" class="anchor"></span><div class="para"> <p> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183678" data-toggle="tooltip" title="Angiotensin receptor/neprilysin inhibitors (ARNIs)" data-id="0d568aff-df91-4de2-98d0-4d9892824bde" data-itemid="8421724d-323b-4c1e-a65f-97616ef1e639">Angiotensin receptor/neprilysin inhibitors (ARNIs)</a><span id="0d568aff-df91-4de2-98d0-4d9892824bde" class="d-none xref"> <span class="tooltip-container"> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183678"> <span class="tooltip-content"> <span class="tooltip-heading"> Angiotensin receptor/neprilysin inhibitors (ARNIs) </span> Heart failure (HF) is a syndrome of ventricular dysfunction (see Heart Failure). Drug treatment of heart failure (HF) involves symptom relief with Diuretics Nitrates Digoxin <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span></p></div></li><li class="topic__listitem"><span id="v71486520" class="anchor"></span><div class="para"> <p> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183729" data-toggle="tooltip" title="Sodium-glucose cotransporter-2 inhibitors (SGLT2i)" data-id="e88e8513-eab8-47bd-adbe-552130aee58a" data-itemid="8421724d-323b-4c1e-a65f-97616ef1e639">Sodium-glucose cotransporter-2 inhibitors (SGLT2)</a><span id="e88e8513-eab8-47bd-adbe-552130aee58a" class="d-none xref"> <span class="tooltip-container"> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183729"> <span class="tooltip-content"> <span class="tooltip-heading"> Sodium-glucose cotransporter-2 inhibitors (SGLT2i) </span> Heart failure (HF) is a syndrome of ventricular dysfunction (see Heart Failure). Drug treatment of heart failure (HF) involves symptom relief with Diuretics Nitrates Digoxin <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span></p></div></li><li class="topic__listitem"><span id="v71486523" class="anchor"></span><div class="para"> <p> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183722" data-toggle="tooltip" title="Sinus node inhibitors" data-id="eaf9d1bf-975a-4ae6-9ac9-f81fda3f4a12" data-itemid="8421724d-323b-4c1e-a65f-97616ef1e639">Sinus node inhibitors</a><span id="eaf9d1bf-975a-4ae6-9ac9-f81fda3f4a12" class="d-none xref"> <span class="tooltip-container"> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183722"> <span class="tooltip-content"> <span class="tooltip-heading"> Sinus node inhibitors </span> Heart failure (HF) is a syndrome of ventricular dysfunction (see Heart Failure). Drug treatment of heart failure (HF) involves symptom relief with Diuretics Nitrates Digoxin <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span></p></div></li></ul></div><span id="v71486525" class="anchor"></span><div class="para"> <p>All patients should be given clear and explicit information about their drugs, including </p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v71486528" class="anchor"></span><div class="para"> <p>The importance of timely prescription renewal</p></div></li><li class="topic__listitem"><span id="v71486530" class="anchor"></span><div class="para"> <p>The importance of adherence to therapy</p></div></li><li class="topic__listitem"><span id="v71486532" class="anchor"></span><div class="para"> <p>How to recognize adverse effects</p></div></li><li class="topic__listitem"><span id="v71486534" class="anchor"></span><div class="para"> <p>When to contact their physician</p></div></li></ul></div> <section id="v46183625" class="topic__section GHead"> <span></span> <h2 id="" class="topic__header--section"> <span id="v46183626" class="anchor"></span> Selection of drugs for heart failure </h2> <div class="topic__content"> <span id="v46183627" class="anchor"></span><div class="para"> <p>Choice of drug depends on the type of heart failure along with individual patient characteristics. The most common classification of heart failure currently in use stratifies patients into </p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v46183630" class="anchor"></span><div class="para"> <p> <a href="./{B4986CFA-B2A7-45D5-B89B-470DF0EAD991}.html#v935904" data-toggle="tooltip" title="Heart failure with preserved ejection fraction (HFpEF)" data-id="351bf8b1-e073-4714-8418-43d3726027f0" data-itemid="b4986cfa-b2a7-45d5-b89b-470df0ead991">Heart failure with reduced ejection fraction</a><span id="351bf8b1-e073-4714-8418-43d3726027f0" class="d-none xref"> <span class="tooltip-container"> <a href="./{B4986CFA-B2A7-45D5-B89B-470DF0EAD991}.html#v935904"> <span class="tooltip-content"> <span class="tooltip-heading"> Heart failure with preserved ejection fraction (HFpEF) </span> Heart failure (HF) is a syndrome of ventricular dysfunction. Left ventricular (LV) failure causes shortness of breath and fatigue, and right ventricular (RV) failure causes peripheral and abdominal... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/3/2/a/32a-and-32b-chest-xray-patient-bilateral-pleural-effusions.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Heart failure with preserved ejection fraction (HFpEF)" loading="lazy"> </span> </a> </span> </span> ("systolic HF") </p></div></li><li class="topic__listitem"><span id="v46183633" class="anchor"></span><div class="para"> <p> <a href="./{B4986CFA-B2A7-45D5-B89B-470DF0EAD991}.html#v935904" data-toggle="tooltip" title="Heart failure with preserved ejection fraction (HFpEF)" data-id="bb91f201-cb98-4744-af1b-a2621c053efe" data-itemid="b4986cfa-b2a7-45d5-b89b-470df0ead991">Heart failure with preserved ejection fraction</a><span id="bb91f201-cb98-4744-af1b-a2621c053efe" class="d-none xref"> <span class="tooltip-container"> <a href="./{B4986CFA-B2A7-45D5-B89B-470DF0EAD991}.html#v935904"> <span class="tooltip-content"> <span class="tooltip-heading"> Heart failure with preserved ejection fraction (HFpEF) </span> Heart failure (HF) is a syndrome of ventricular dysfunction. Left ventricular (LV) failure causes shortness of breath and fatigue, and right ventricular (RV) failure causes peripheral and abdominal... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/3/2/a/32a-and-32b-chest-xray-patient-bilateral-pleural-effusions.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Heart failure with preserved ejection fraction (HFpEF)" loading="lazy"> </span> </a> </span> </span> ("diastolic HF")</p></div></li><li class="topic__listitem"><span id="v46183636" class="anchor"></span><div class="para"> <p> <a href="./{B4986CFA-B2A7-45D5-B89B-470DF0EAD991}.html#v46183497" data-toggle="tooltip" title="Heart failure with mildly reduced ejection fraction (HFmrEF)" data-id="4baddbb8-8bd9-4d16-bcf3-6e5022b49e04" data-itemid="b4986cfa-b2a7-45d5-b89b-470df0ead991">Heart failure with mildly reduced ejection fraction</a><span id="4baddbb8-8bd9-4d16-bcf3-6e5022b49e04" class="d-none xref"> <span class="tooltip-container"> <a href="./{B4986CFA-B2A7-45D5-B89B-470DF0EAD991}.html#v46183497"> <span class="tooltip-content"> <span class="tooltip-heading"> Heart failure with mildly reduced ejection fraction (HFmrEF) </span> Heart failure (HF) is a syndrome of ventricular dysfunction. Left ventricular (LV) failure causes shortness of breath and fatigue, and right ventricular (RV) failure causes peripheral and abdominal... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/3/2/a/32a-and-32b-chest-xray-patient-bilateral-pleural-effusions.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Heart failure with mildly reduced ejection fraction (HFmrEF)" loading="lazy"> </span> </a> </span> </span></p></div></li></ul></div><span id="v71486538" class="anchor"></span><div class="para"> <p><b>Heart failure with reduced ejection fraction (HFrEF)</b></p></div><span id="v46183638" class="anchor"></span><div class="para"> <p>In HFrEF standard of care includes the following four classes of therapies, considered to be 'foundational therapies' for HFrEF management:</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v71486541" class="anchor"></span><div class="para"> <p>Beta-blocker</p></div></li><li class="topic__listitem"><span id="v71486543" class="anchor"></span><div class="para"> <p>Renin-angiotensin-aldosterone system (RAAS) inhibitor(typically an ARNI, although an ACE inhibitor or ARB could also used if ARNI is not tolerated)</p></div></li><li class="topic__listitem"><span id="v71486545" class="anchor"></span><div class="para"> <p>Aldosterone antagonist</p></div></li><li class="topic__listitem"><span id="v71486547" class="anchor"></span><div class="para"> <p>SGLT2</p></div></li></ul></div><span id="v71486548" class="anchor"></span><div class="para"> <p>These four drug classes have been studied and have shown benefit for long-term management of HFrEF. Therapy is typically titrated up to maximal tolerated doses. Patients are typically given a drug from each class. Because patients may already be taking one of these classes of drugs prior to developing heart failure, the order of therapy initiation and rate of up-titration are generally patient specific. </p></div><span id="v71486549" class="anchor"></span><div class="para"> <p>Addition of a <a href="./{912A66B5-650E-4099-A978-4C78E044364D}.html#v29300303" data-toggle="tooltip" title="Sodium-glucose co-transporter 2 inhibitors" data-id="15436bcc-a197-4e2f-960e-9a41f9028527" data-itemid="912a66b5-650e-4099-a978-4c78e044364d">sodium-glucose cotransporter-2 (SGLT2) inhibitor</a><span id="15436bcc-a197-4e2f-960e-9a41f9028527" class="d-none xref"> <span class="tooltip-container"> <a href="./{912A66B5-650E-4099-A978-4C78E044364D}.html#v29300303"> <span class="tooltip-content"> <span class="tooltip-heading"> Sodium-glucose co-transporter 2 inhibitors </span> General treatment of diabetes mellitus for all patients involves lifestyle changes, including diet and exercise. Appropriate monitoring and control of blood glucose levels is essential to prevent... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>, either <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>dapagliflozin</span> or <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>empagliflozin</span> (<a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v71486564" data-toggle="tooltip" title="Drug selection references" data-id="c22bebef-f12c-433f-8fba-b111503b871d" data-itemid="8421724d-323b-4c1e-a65f-97616ef1e639">1</a><span id="c22bebef-f12c-433f-8fba-b111503b871d" class="d-none xref"> <span class="tooltip-container"> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v71486564"> <span class="tooltip-content"> <span class="tooltip-heading"> Drug selection references </span> Heart failure (HF) is a syndrome of ventricular dysfunction (see Heart Failure). Drug treatment of heart failure (HF) involves symptom relief with Diuretics Nitrates Digoxin <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>), has been shown to reduce morbidity and mortality when added to standard care in patients with elevated natriuretic peptide levels; benefit was similar in patients with and without <a href="./{C638B386-4B60-444C-8A50-BD90E6B9D85D}.html" data-toggle="tooltip" title="Diabetes Mellitus (DM)" data-id="86d94ff1-d2b5-4d53-a4c7-0a2e98290c35" data-itemid="c638b386-4b60-444c-8a50-bd90e6b9d85d">diabetes</a><span id="86d94ff1-d2b5-4d53-a4c7-0a2e98290c35" class="d-none xref"> <span class="tooltip-container"> <a href="./{C638B386-4B60-444C-8A50-BD90E6B9D85D}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Diabetes Mellitus (DM) </span> Diabetes mellitus is impaired insulin secretion and variable degrees of peripheral insulin resistance leading to hyperglycemia. Early symptoms are related to hyperglycemia and include polydipsia... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>.</p></div><span id="v71486553" class="anchor"></span><div class="para"> <p>Other therapies are used in patient-specific settings (eg, sinus node inhibitors for lowering heart rate if patients cannot tolerate beta blockers).</p></div><span id="v71486554" class="anchor"></span><div class="para"> <p><b>Heart failure with preserved ejection fraction (HFpEF)</b></p></div><span id="v46183640" class="anchor"></span><div class="para"> <p>In HFpEF fewer drugs have been adequately studied. However, ACE inhibitors, ARBs, or aldosterone antagonists (mineralocorticoid receptor antagonists) are often used to treat HFpEF and/or associated comorbidities (such as hypertension and renal dysfunction), although survival benefit has not been demonstrated in clinical trials and, therefore, are not considered a standard of care. </p></div><span id="v71486555" class="anchor"></span><div class="para"> <p>ARNIs may reduce hospitalizations for heart failure but do not improve other outcomes. </p></div><span id="v71486556" class="anchor"></span><div class="para"> <p>In a recent clinical trial, the addition of the SGLT2 inhibitor <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>empagliflozin</span> to usual therapy was shown to reduce mortality and hospitalizations for HFpEF (<a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v71486564" data-toggle="tooltip" title="Drug selection references" data-id="c201cfc0-156a-406d-b50a-a8df196720c5" data-itemid="8421724d-323b-4c1e-a65f-97616ef1e639">2</a><span id="c201cfc0-156a-406d-b50a-a8df196720c5" class="d-none xref"> <span class="tooltip-container"> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v71486564"> <span class="tooltip-content"> <span class="tooltip-heading"> Drug selection references </span> Heart failure (HF) is a syndrome of ventricular dysfunction (see Heart Failure). Drug treatment of heart failure (HF) involves symptom relief with Diuretics Nitrates Digoxin <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>). </p></div><span id="v71486558" class="anchor"></span><div class="para"> <p>Beta blockers should be used only when there is another existing indication (eg, control of heart rate during atrial fibrillation, angina, following myocardial infarction). In patients with severe HFpEF (in contrast to HFrEF), lowering the heart rate (eg, with a beta-blocker) can exacerbate symptoms because they have a relatively fixed stroke volume due to severe diastolic dysfunction. In these patients, cardiac output (CO) is heart rate dependent, and lowering heart rate can thus lower CO at rest and/or with exertion. </p></div><span id="v71486559" class="anchor"></span><div class="para"> <p>In patients with infiltrative, restrictive, or <a href="./{BCB4C7FA-246E-4116-8AD2-049B1C4F4B42}.html" data-toggle="tooltip" title="Hypertrophic Cardiomyopathy" data-id="918f2262-5e24-4d4e-9524-8d19afa99b1d" data-itemid="bcb4c7fa-246e-4116-8ad2-049b1c4f4b42">hypertrophic cardiomyopathy</a><span id="918f2262-5e24-4d4e-9524-8d19afa99b1d" class="d-none xref"> <span class="tooltip-container"> <a href="./{BCB4C7FA-246E-4116-8AD2-049B1C4F4B42}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Hypertrophic Cardiomyopathy </span> Hypertrophic cardiomyopathy is a congenital or acquired disorder characterized by marked ventricular hypertrophy with diastolic dysfunction (eg, due to valvular aortic stenosis, coarctation... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/1/1/c/11-cardiac-mri-showing-hypertrophic-cardiomypathy-ctisus.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Hypertrophic Cardiomyopathy" loading="lazy"> </span> </a> </span> </span>, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>digoxin</span> is not effective and may be harmful. In addition, vasodilator therapy may also be poorly tolerated and has not shown benefit in these patients. </p></div><span id="v71486561" class="anchor"></span><div class="para"> <p><b>Heart failure with mildly reduced ejection fraction (HFmrEF)</b></p></div><span id="v46183641" class="anchor"></span><div class="para"> <p>In HFmrEF there may be a specific benefit from ARNIs, although this possibility requires confirmation. </p></div><span id="v71486562" class="anchor"></span><div class="para"> <p>Patients with HFmrEF also benefit from the addition of an SGLT2 inhibitor such as <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>empagliflozin</span> to standard care. </p></div> </div> </section> <section id="v71486563" class="topic__section GHead"> <span></span> <h2 id="" class="topic__header--section"> <span id="v71486564" class="anchor"></span> Drug selection references </h2> <div class="topic__content"> <div class="list"> <ul data-mmanualobjecttype="List" class="nobulleted"><li class="topic__listitem"><span id="v71486567" class="anchor"></span><div class="para"> <p>1. <a rel="nofollow" target="_blank" href="https://pubmed.ncbi.nlm.nih.gov/32865377/">Packer M, Anker SD, Butler J, et al</a>: Cardiovascular and renal outcomes with <span class="genericDrug" data-showrollover="false">empagliflozin</span> in heart failure. <i>N Engl J Med</i> 383(15):1413-1424, 2020. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28. PMID: 32865377.</p></div></li><li class="topic__listitem"><span id="v71486571" class="anchor"></span><div class="para"> <p>2. <a rel="nofollow" target="_blank" href="https://pubmed.ncbi.nlm.nih.gov/34449189/">Anker SD, Butler J, Filippatos G, et al</a>: <span class="genericDrug" data-showrollover="false">Empagliflozin</span> in heart failure with a preserved ejection fraction. <i>N Engl J Med</i> 385(16):1451-1461, 2021. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27. PMID: 34449189. </p></div></li></ul></div> </div> </section> <section id="v46183645" class="topic__section FHead"> <h2 id="" class="topic__header--section"> <span id="v46183646" class="anchor"></span> Classes of Drugs for Heart Failure </h2> <div class="topic__content"> <section id="v46183647" class="topic__section GHead"> <span></span> <h3 id="" class="topic__header--subsection"> <span id="v46183648" class="anchor"></span> Aldosterone antagonists </h3> <div class="topic__content"> <span id="v46183649" class="anchor"></span><div class="para"> <p>Because aldosterone can be produced independently of the renin-angiotensin system, its adverse effects are not inhibited completely even by maximal use of ACE inhibitors and <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>angiotensin II</span> receptor blockers (ARBs). Thus, the aldosterone antagonists (also termed mineralocorticoid receptor antagonists) are often used, particularly for patients with <a href="./{B4986CFA-B2A7-45D5-B89B-470DF0EAD991}.html#v936076" data-toggle="tooltip" title="Symptoms and Signs" data-id="f293bb10-fef8-44ee-aa90-e9afc34e2811" data-itemid="b4986cfa-b2a7-45d5-b89b-470df0ead991">moderate to severe symptoms</a><span id="f293bb10-fef8-44ee-aa90-e9afc34e2811" class="d-none xref"> <span class="tooltip-container"> <a href="./{B4986CFA-B2A7-45D5-B89B-470DF0EAD991}.html#v936076"> <span class="tooltip-content"> <span class="tooltip-heading"> Symptoms and Signs </span> Heart failure (HF) is a syndrome of ventricular dysfunction. Left ventricular (LV) failure causes shortness of breath and fatigue, and right ventricular (RV) failure causes peripheral and abdominal... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/3/2/a/32a-and-32b-chest-xray-patient-bilateral-pleural-effusions.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Symptoms and Signs" loading="lazy"> </span> </a> </span> </span> or signs of heart failure. </p></div><span id="v46183650" class="anchor"></span><div class="para"> <p>Typical drugs include <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>spironolactone</span> 25 to 50 mg orally once a day and <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>eplerenone</span> 25 to 100 mg orally once a day (does not cause gynecomastia in males). Aldosterone antagonists can reduce mortality, including from sudden death, in patients with left ventricular ejection fraction (LVEF) <span class='symbol'>&lt</span> 30% and chronic HF, or acute HF complicating <a href="./{1FE201C9-088A-4951-838B-B2C8BB45A77E}.html" data-toggle="tooltip" title="Acute Myocardial Infarction (MI)" data-id="474c7915-13ff-434f-bc10-112310067dad" data-itemid="1fe201c9-088a-4951-838b-b2c8bb45a77e">acute myocardial infarction</a><span id="474c7915-13ff-434f-bc10-112310067dad" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FE201C9-088A-4951-838B-B2C8BB45A77E}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Acute Myocardial Infarction (MI) </span> Acute myocardial infarction is myocardial necrosis resulting from acute obstruction of a coronary artery. Symptoms include chest discomfort with or without dyspnea, nausea, and/or diaphoresis... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/6/0/0/600-nstemi-s192-springer-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Acute Myocardial Infarction (MI)" loading="lazy"> </span> </a> </span> </span>. </p></div><span id="v46183651" class="anchor"></span><div class="para"> <p>Potassium supplements should be stopped. Serum potassium and creatinine should be checked every 1 to 2 weeks for the first 4 to 6 weeks and after dose changes. Dose is lowered if potassium is between 5.0 and 5.5 mEq/L ( 5.5 mmol/L) and stopped if potassium is <span class='symbol'>></span> 5.5 mEq/L (5.5 mmol/L), if creatinine increases above 2.5 mg/dL (220 micromol/L), or if ECG changes of hyperkalemia are present. Aldosterone antagonists should not be used in patients receiving both an ACE inhibitor and an ARB because of the high risk of <a href="./{2F836CB2-5211-46FB-B1C6-28BB79FC979B}.html" data-toggle="tooltip" title="Hyperkalemia" data-id="944856eb-0eea-4f54-bbca-68e450c79a55" data-itemid="2f836cb2-5211-46fb-b1c6-28bb79fc979b">hyperkalemia</a><span id="944856eb-0eea-4f54-bbca-68e450c79a55" class="d-none xref"> <span class="tooltip-container"> <a href="./{2F836CB2-5211-46FB-B1C6-28BB79FC979B}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Hyperkalemia </span> Hyperkalemia is a serum potassium concentration > 5.5 mEq/L (> 5.5 mmol/L), usually resulting from decreased renal potassium excretion or abnormal movement of potassium out of cells. There... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span> and renal dysfunction. </p></div><span id="v46183653" class="anchor"></span><div class="para"> <p>In <b>patients with HFrEF,</b> an aldosterone antagonist plus either an ACE inhibitor or an ARB is preferred over the combination of an ACE inhibitor and ARB. </p></div><span id="v46183654" class="anchor"></span><div class="para"> <p>In <b>patients with HFpEF,</b> <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>spironolactone</span> reduces hospitalization for heart failure and likely reduces cardiovascular mortality (<a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183753" data-toggle="tooltip" title="Drug treatment references" data-id="e300766b-a45a-4ce7-98e1-92a2b77cc92a" data-itemid="8421724d-323b-4c1e-a65f-97616ef1e639">1</a><span id="e300766b-a45a-4ce7-98e1-92a2b77cc92a" class="d-none xref"> <span class="tooltip-container"> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183753"> <span class="tooltip-content"> <span class="tooltip-heading"> Drug treatment references </span> Heart failure (HF) is a syndrome of ventricular dysfunction (see Heart Failure). Drug treatment of heart failure (HF) involves symptom relief with Diuretics Nitrates Digoxin <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>). Thus, aldosterone antagonists should be used in patients with HFpEF, particularly if they are volume overloaded and/or have a history of HF hospitalization. Loop diuretics can be minimized if necessary to accommodate the use of aldosterone antagonists. </p></div> </div> </section> <section id="v46183656" class="topic__section GHead"> <span></span> <h3 id="" class="topic__header--subsection"> <span id="v46183657" class="anchor"></span> Angiotensin converting enzyme (ACE) inhibitors </h3> <div class="topic__content"> <span id="v46183658" class="anchor"></span><div class="para"> <p>All <b>patients with HFrEF</b> should be given oral ACE inhibitors unless contraindicated (eg, by plasma creatinine <span class='symbol'>></span> 2.8 mg/dL [<span class='symbol'>></span> 250 micromol/L], bilateral <a href="./{845BD427-6E5E-479A-9B19-F168FD00F478}.html" data-toggle="tooltip" title="Renal Artery Stenosis and Occlusion" data-id="1bc2a96c-9550-4be5-8e7e-0fe925b52e9b" data-itemid="845bd427-6e5e-479a-9b19-f168fd00f478">renal artery stenosis</a><span id="1bc2a96c-9550-4be5-8e7e-0fe925b52e9b" class="d-none xref"> <span class="tooltip-container"> <a href="./{845BD427-6E5E-479A-9B19-F168FD00F478}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Renal Artery Stenosis and Occlusion </span> Renal artery stenosis is a decrease in blood flow through one or both of the main renal arteries or their branches. Renal artery occlusion is a complete blockage of blood flow through one or... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/r/e/n/renal_artery_stenosis_digital_subtraction_angiography_high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Renal Artery Stenosis and Occlusion" loading="lazy"> </span> </a> </span> </span>, renal artery stenosis in a solitary kidney, or previous angioedema due to ACE inhibitors).</p></div><span id="v46183659" class="anchor"></span><div class="para"> <p>ACE inhibitors reduce production of <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>angiotensin II</span> and breakdown of bradykinin, mediators that affect the sympathetic nervous system, endothelial function, vascular tone, and myocardial performance. Hemodynamic effects include </p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v50500247" class="anchor"></span><div class="para"> <p>Arterial and venous vasodilation</p></div></li><li class="topic__listitem"><span id="v50500249" class="anchor"></span><div class="para"> <p>Sustained decreases in LV filling pressure during rest and exercise</p></div></li><li class="topic__listitem"><span id="v50500251" class="anchor"></span><div class="para"> <p>Decreased systemic vascular resistance</p></div></li><li class="topic__listitem"><span id="v50500253" class="anchor"></span><div class="para"> <p>Favorable effects on ventricular remodeling</p></div></li></ul></div><span id="v50500254" class="anchor"></span><div class="para"> <p>ACE inhibitors prolong survival and reduce HF hospitalizations. For patients with <a href="./{2E89ECA0-4144-42F5-A042-99D82FF08250}.html" data-toggle="tooltip" title="Atherosclerosis" data-id="ad6c38e1-e210-4616-abc5-f538abbfc80a" data-itemid="2e89eca0-4144-42f5-a042-99d82ff08250">atherosclerosis</a><span id="ad6c38e1-e210-4616-abc5-f538abbfc80a" class="d-none xref"> <span class="tooltip-container"> <a href="./{2E89ECA0-4144-42F5-A042-99D82FF08250}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Atherosclerosis </span> Atherosclerosis is characterized by patchy intimal plaques (atheromas) that encroach on the lumen of medium-sized and large arteries. The plaques contain lipids, inflammatory cells, smooth muscle... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/1/7/m1750135-atherosclerotic-plaque-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Atherosclerosis" loading="lazy"> </span> </a> </span> </span> and a vascular disorder, these drugs reduce the risk of myocardial infarction and stroke. For patients with diabetes, they delay onset of nephropathy. Thus, ACE inhibitors may be used in patients with diastolic dysfunction and any of these disorders.</p></div><span id="v46183660" class="anchor"></span><div class="para"> <p>The starting dose typically should be low (usually one fourth to one half of the target dose depending on blood pressure and renal function); the dose is gradually adjusted upward over 8 weeks as tolerated, then continued indefinitely. Usual target doses of representative drugs include <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>enalapril</span> 10 to 20 mg twice a day, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>lisinopril</span> 20 to 30 mg once a day, and <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>ramipril</span> 5 mg twice a day; there are many others.</p></div><span id="v46183661" class="anchor"></span><div class="para"> <p>If the hypotensive effect (more marked in patients with hyponatremia or volume depletion) is troublesome, it can often be minimized by separating administration of other blood pressure–lowering drugs, reducing the dose of concomitant diuretics, using a longer acting ACE inhibitor (eg, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>perindopril</span>), or giving the dose at bedtime. ACE inhibitors often cause mild to moderate reversible serum creatinine elevation due to vasodilation of the efferent glomerular arteriole. An initial 20 to 30% increase in creatinine is no reason to stop the drug but does require closer monitoring, slower increases in dose, reduction in diuretic dose, or avoidance of nonsteroidal anti-inflammatory drugs (NSAIDs). Because aldosterone’s effect is reduced, potassium retention (<a href="./{2F836CB2-5211-46FB-B1C6-28BB79FC979B}.html" data-toggle="tooltip" title="Hyperkalemia" data-id="0b38909b-0e52-4dad-b343-cc37fbcd5569" data-itemid="2f836cb2-5211-46fb-b1c6-28bb79fc979b">hyperkalemia</a><span id="0b38909b-0e52-4dad-b343-cc37fbcd5569" class="d-none xref"> <span class="tooltip-container"> <a href="./{2F836CB2-5211-46FB-B1C6-28BB79FC979B}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Hyperkalemia </span> Hyperkalemia is a serum potassium concentration > 5.5 mEq/L (> 5.5 mmol/L), usually resulting from decreased renal potassium excretion or abnormal movement of potassium out of cells. There... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>) may result, especially in patients receiving potassium supplements. Cough occurs in 5 to 15% of patients, probably because bradykinin accumulates, but other causes of cough should also be considered. Occasionally, rash or dysgeusia occurs. <a href="./{C0F72208-E822-4428-8006-ECB71CA60E95}.html" data-toggle="tooltip" title="Angioedema" data-id="e5221457-32d2-448a-9774-ba06f92b8513" data-itemid="c0f72208-e822-4428-8006-ecb71ca60e95">Angioedema</a><span id="e5221457-32d2-448a-9774-ba06f92b8513" class="d-none xref"> <span class="tooltip-container"> <a href="./{C0F72208-E822-4428-8006-ECB71CA60E95}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Angioedema </span> Angioedema is edema of the deep dermis and subcutaneous tissues. It is usually an acute but sometimes a chronic mast cell–mediated reaction caused by exposure to a drug (eg, angiotensin-converting... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/a/n/g/angioedema_high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Angioedema" loading="lazy"> </span> </a> </span> </span> is rare but can be life threatening and is a contraindication to ACE inhibitors. Alternatively, ARBs can be used, although rarely cross-reactivity is reported. Both are contraindicated in pregnancy.</p></div><span id="v46183664" class="anchor"></span><div class="para"> <p>Serum electrolytes and renal function should be measured before an ACE inhibitor is started, at 1 month, and after each significant increase in dose or change in clinical condition. If dehydration or poor renal function due to acute illness develops, the ACE inhibitor dose may need to be reduced or the drug may be temporarily stopped.</p></div><span id="v46183665" class="anchor"></span><div class="para"> <p>In <b>HFpEF,</b> a randomized controlled trial of the ACE inhibitor <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>perindopril</span> demonstrated improved exercise capacity. It did not improve survival, although there was a high rate of crossover from placebo to ACE inhibitor in this trial (<a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183753" data-toggle="tooltip" title="Drug treatment references" data-id="4b1b4317-bbb7-48b0-ba73-9b30d0c76544" data-itemid="8421724d-323b-4c1e-a65f-97616ef1e639">2</a><span id="4b1b4317-bbb7-48b0-ba73-9b30d0c76544" class="d-none xref"> <span class="tooltip-container"> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183753"> <span class="tooltip-content"> <span class="tooltip-heading"> Drug treatment references </span> Heart failure (HF) is a syndrome of ventricular dysfunction (see Heart Failure). Drug treatment of heart failure (HF) involves symptom relief with Diuretics Nitrates Digoxin <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>). Given the very high prevalence of hypertension in HFpEF, it is reasonable to use an ACE inhibitor to control hypertension in these patients as these drugs may have secondary beneficial effects on exercise capacity in these patients. </p></div> </div> </section> <section id="v46183667" class="topic__section GHead"> <span></span> <h3 id="" class="topic__header--subsection"> <span id="v46183668" class="anchor"></span> Angiotensin II receptor blockers (ARBs) </h3> <div class="topic__content"> <span id="v46183669" class="anchor"></span><div class="para"> <p>These drugs are not demonstrably superior to ACE inhibitors but are less likely to cause cough and angioedema; they may be used when these adverse effects prohibit ACE inhibitor use. </p></div><span id="v46183670" class="anchor"></span><div class="para"> <p>In <b>chronic HFrEF,</b> ACE inhibitors and ARBs are likely equally effective. Usual oral target doses are <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>valsartan</span> 160 mg twice a day, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>candesartan</span> 32 mg once a day, and <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>losartan</span> 50 to 100 mg once a day. Introduction, upward dose adjustment, and monitoring of ARBs and ACE inhibitors are similar. Like ACE inhibitors, ARBs can cause reversible renal dysfunction, and the dose may need to be reduced or stopped temporarily during an acute dehydrating illness.</p></div><span id="v46183671" class="anchor"></span><div class="para"> <p>Adding an ARB to a regimen of an ACE inhibitor, beta-blocker, and aldosterone antagonist is unlikely to be helpful and should be avoided given the risk of <a href="./{2F836CB2-5211-46FB-B1C6-28BB79FC979B}.html" data-toggle="tooltip" title="Hyperkalemia" data-id="3862776f-362b-4f1d-9a83-76f94a888fb3" data-itemid="2f836cb2-5211-46fb-b1c6-28bb79fc979b">hyperkalemia</a><span id="3862776f-362b-4f1d-9a83-76f94a888fb3" class="d-none xref"> <span class="tooltip-container"> <a href="./{2F836CB2-5211-46FB-B1C6-28BB79FC979B}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Hyperkalemia </span> Hyperkalemia is a serum potassium concentration > 5.5 mEq/L (> 5.5 mmol/L), usually resulting from decreased renal potassium excretion or abnormal movement of potassium out of cells. There... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>. If a patient who is taking an ACE inhibitor or ARB is still symptomatic, an aldosterone antagonist should be started and/or an angiotensin receptor/neprilysin inhibitor (ARNI) should be used. </p></div><span id="v46183673" class="anchor"></span><div class="para"> <p>In <b>HFpEF,</b> a large randomized controlled trial of <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>candesartan</span> (<a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183753" data-toggle="tooltip" title="Drug treatment references" data-id="55819809-6d89-4cf0-b494-ecd3defaf93c" data-itemid="8421724d-323b-4c1e-a65f-97616ef1e639">3</a><span id="55819809-6d89-4cf0-b494-ecd3defaf93c" class="d-none xref"> <span class="tooltip-container"> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183753"> <span class="tooltip-content"> <span class="tooltip-heading"> Drug treatment references </span> Heart failure (HF) is a syndrome of ventricular dysfunction (see Heart Failure). Drug treatment of heart failure (HF) involves symptom relief with Diuretics Nitrates Digoxin <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>) demonstrated reduced number of hospitalizations for recurrent HF; however, hospitalization was a secondary endpoint. In another trial (<a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183753" data-toggle="tooltip" title="Drug treatment references" data-id="29d51a84-8b47-4c3f-9095-4960bdd348d3" data-itemid="8421724d-323b-4c1e-a65f-97616ef1e639">4</a><span id="29d51a84-8b47-4c3f-9095-4960bdd348d3" class="d-none xref"> <span class="tooltip-container"> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183753"> <span class="tooltip-content"> <span class="tooltip-heading"> Drug treatment references </span> Heart failure (HF) is a syndrome of ventricular dysfunction (see Heart Failure). Drug treatment of heart failure (HF) involves symptom relief with Diuretics Nitrates Digoxin <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>), <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>irbesartan</span> was not associated with any improvement in outcomes in HFpEF. Therefore, ARBs should be used in HFpEF only if they are already being used to treat hypertension, diabetic kidney disease, or microalbuminuria. </p></div><span id="v46183676" class="anchor"></span><div class="para"> <p>ARBs are contraindicated in pregnancy.</p></div> </div> </section> <section id="v46183677" class="topic__section GHead"> <span></span> <h3 id="" class="topic__header--subsection"> <span id="v46183678" class="anchor"></span> Angiotensin receptor/neprilysin inhibitors (ARNIs) </h3> <div class="topic__content"> <span id="v46183679" class="anchor"></span><div class="para"> <p>ARNIs are a new combination drug for the treatment of heart failure. They include an ARB and a newer class of drug, neprilysin inhibitors (eg, sacubitril). Neprilysin is an enzyme involved in the breakdown of vasoactive substances such as brain (B-type) natriuretic peptide (BNP) and other peptides. By inhibiting the breakdown of BNP and other beneficial vasoactive peptides, these drugs lower blood pressure, decrease afterload, and enhance natriuresis. Because neprilysin inhibitors increase BNP levels, NTproBNP levels (which are not increased by the drug) should be used instead to help diagnose and manage HF. </p></div><span id="v46183680" class="anchor"></span><div class="para"> <p>In <b>HFrEF,</b> a large randomized, controlled trial (<a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183753" data-toggle="tooltip" title="Drug treatment references" data-id="99a6e0d4-f9d7-47b4-b8d6-1406a2b76627" data-itemid="8421724d-323b-4c1e-a65f-97616ef1e639">5</a><span id="99a6e0d4-f9d7-47b4-b8d6-1406a2b76627" class="d-none xref"> <span class="tooltip-container"> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183753"> <span class="tooltip-content"> <span class="tooltip-heading"> Drug treatment references </span> Heart failure (HF) is a syndrome of ventricular dysfunction (see Heart Failure). Drug treatment of heart failure (HF) involves symptom relief with Diuretics Nitrates Digoxin <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>) compared <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>sacubitril/valsartan</span> to <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>enalapril</span> in patients with NYHA (New York Heart Association) class II through IV heart failure (see table <span class="multimedia__link mlinkBlock" data-bind="component: { name: 'm-link-text', params: $data }" data-popup-model='{"ItemId":"1eb88a9a-a642-4893-be34-e8ce67f84ade","Title":"New%20York%20Heart%20Association%20%28NYHA%29%20Classification%20of%20Heart%20Failure","ShareUrlTitle":"new-york-heart-association-nyha-classification-of-heart-failure","Description":"","ImageUrl":null,"ThumbnailUrl":"/Content/Images/Redesign/table/icon_table_red.png","MediaType":"table","MediaNameTranslated":"Table","UniqueId":"v936085","Placement":null,"IsInCarousel":false,"Edition":0,"ImageWidth":null,"ImageHeight":null,"IframeSrc":null,"Target":null,"Alt":null}' data-popup-options='{"ListName":"TopicMultimedia","LinkText":"%3Cspan%20%3ENYHA%20Classification%20of%20Heart%20Failure%3C%2Fspan%3E","CssClass":null,"LoadLocations":true,"ShowTooltip":true,"SingleItem":true,"ExcludeFromBrand":"","ShowCredits":true,"ShowDescription":true,"PopupTitle":"Table","ShowTitle":true,"ShowIcon":false,"ShowModalIndicator":false,"ShowTitleInHeader":false,"HideCarousel":false,"Target":"modal","Url":null,"HideMainArrows":false}'></span>). <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Sacubitril/valsartan</span> reduced the primary endpoints of combined cardiovascular mortality or hospitalizations for HF; the number needed to treat was 21. <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Sacubitril/valsartan</span> also reduced all-cause mortality. Thus, the ARNI <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>sacubitril/valsartan</span> should be considered in all patients with stable HFrEF, particularly those with NYHA class II or III symptoms on optimal guideline-directed medical therapy and who have elevated natriuretic peptide levels before starting treatment. Evidence supports early transition of patients from ACE/ARB to ARNI, even in the hospital setting where patients will experience less pulmonary congestion and may have fewer early readmissions.</p></div><span id="v46183683" class="anchor"></span><div class="para"> <p>There are 3 strengths of <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>sacubitril/valsartan</span>: 24/26 mg, 49/51 mg, and 97/103 mg, all are taken orally twice a day. The starting dose is 49/51 mg orally twice a day for patients previously taking an ACE inhibitor or ARB, and 24/26 mg for patients previously taking a low dose of an ACE inhibitor or ARB (eg, ≤ 10 mg <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>enalapril</span> daily) or in those patients who are ACE inhibitor/ARB naive or who have low/borderline blood pressure. ACE inhibitors must be discontinued 36 hours before initiation of <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>sacubitril/valsartan</span>. Patients previously taking an ARB can simply switch to <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>sacubitril/valsartan</span> without a washout period.</p></div><span id="v46183684" class="anchor"></span><div class="para"> <p>Complications associated with use of ARNI include hypotension, <a href="./{2F836CB2-5211-46FB-B1C6-28BB79FC979B}.html" data-toggle="tooltip" title="Hyperkalemia" data-id="6c51a852-ec12-456b-93dc-42c9f3aa14ac" data-itemid="2f836cb2-5211-46fb-b1c6-28bb79fc979b">hyperkalemia</a><span id="6c51a852-ec12-456b-93dc-42c9f3aa14ac" class="d-none xref"> <span class="tooltip-container"> <a href="./{2F836CB2-5211-46FB-B1C6-28BB79FC979B}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Hyperkalemia </span> Hyperkalemia is a serum potassium concentration > 5.5 mEq/L (> 5.5 mmol/L), usually resulting from decreased renal potassium excretion or abnormal movement of potassium out of cells. There... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>, renal insufficiency, and <a href="./{C0F72208-E822-4428-8006-ECB71CA60E95}.html" data-toggle="tooltip" title="Angioedema" data-id="72bb7db0-02f7-4240-8c3c-9039d4f6da7d" data-itemid="c0f72208-e822-4428-8006-ecb71ca60e95">angioedema</a><span id="72bb7db0-02f7-4240-8c3c-9039d4f6da7d" class="d-none xref"> <span class="tooltip-container"> <a href="./{C0F72208-E822-4428-8006-ECB71CA60E95}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Angioedema </span> Angioedema is edema of the deep dermis and subcutaneous tissues. It is usually an acute but sometimes a chronic mast cell–mediated reaction caused by exposure to a drug (eg, angiotensin-converting... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/a/n/g/angioedema_high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Angioedema" loading="lazy"> </span> </a> </span> </span>. Sacubitril is coupled with <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>valsartan</span> (an ARB) because of the increased risk of angioedema with the use of sacubitril alone or in combination with an ACE inhibitor. For this reason, combined ACE/ARNI therapy is absolutely contraindicated. </p></div><span id="v46183687" class="anchor"></span><div class="para"> <p>In <b>HFpEF,</b> a phase 2 trial showed that the ARNI <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>sacubitril/valsartan</span> reduced NTproBNP levels at 12 weeks and left atrial volume at 36 weeks. The PARAGON HF study in a stable population of patients with HFpEF showed a non-significant reduction in death and hospitalization (<a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183753" data-toggle="tooltip" title="Drug treatment references" data-id="d4873c80-cdcf-46ad-8ef7-6e7b69eedc96" data-itemid="8421724d-323b-4c1e-a65f-97616ef1e639">6, 7</a><span id="d4873c80-cdcf-46ad-8ef7-6e7b69eedc96" class="d-none xref"> <span class="tooltip-container"> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183753"> <span class="tooltip-content"> <span class="tooltip-heading"> Drug treatment references </span> Heart failure (HF) is a syndrome of ventricular dysfunction (see Heart Failure). Drug treatment of heart failure (HF) involves symptom relief with Diuretics Nitrates Digoxin <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>). However, there may have been lower hospitalization rates—further study is needed. </p></div> </div> </section> <section id="v46183689" class="topic__section GHead"> <span></span> <h3 id="" class="topic__header--subsection"> <span id="v46183690" class="anchor"></span> Beta-blockers </h3> <div class="topic__content"> <span id="v46183691" class="anchor"></span><div class="para"> <p>In <b>patients with HFrEF,</b> beta-blockers, unless otherwise contraindicated (by <a href="./{7E52EFBA-8905-43F4-9408-53B7471DEB80}.html" data-toggle="tooltip" title="Asthma" data-id="109fe1fd-0313-4f12-a106-67b33f3ec09c" data-itemid="7e52efba-8905-43f4-9408-53b7471deb80">asthma</a><span id="109fe1fd-0313-4f12-a106-67b33f3ec09c" class="d-none xref"> <span class="tooltip-container"> <a href="./{7E52EFBA-8905-43F4-9408-53B7471DEB80}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Asthma </span> Asthma is a disease of diffuse airway inflammation caused by a variety of triggering stimuli resulting in partially or completely reversible bronchoconstriction. Symptoms and signs include dyspnea... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>, 2nd- or 3rd-degree <a href="./{6DAA6064-7FA0-4A0C-B5A7-32DCC33D4B03}.html" data-toggle="tooltip" title="Atrioventricular Block" data-id="0f2b3d44-0f59-4670-b0fb-1bbed559b7e2" data-itemid="6daa6064-7fa0-4a0c-b5a7-32dcc33d4b03">atrioventricular block</a><span id="0f2b3d44-0f59-4670-b0fb-1bbed559b7e2" class="d-none xref"> <span class="tooltip-container"> <a href="./{6DAA6064-7FA0-4A0C-B5A7-32DCC33D4B03}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Atrioventricular Block </span> Atrioventricular (AV) block is partial or complete interruption of impulse transmission from the atria to the ventricles. The most common cause is idiopathic fibrosis and sclerosis of the conduction... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/o/b/mobitz-i-four-to-three-cropped-annotated-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Atrioventricular Block" loading="lazy"> </span> </a> </span> </span>, or previous significant intolerance), are critical for the treatment, and an important addition to ACE inhibitors in these patients. In HFrEF, beta-blockers are best started when the patient has no evidence of pulmonary congestion. Specific beta-blockers such as <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>carvedilol</span> and <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>metoprolol</span> succinate (ie, long-acting <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>metoprolol</span>) improve left ventricular ejection fraction, survival, and other major cardiovascular outcomes in patients with chronic HFrEF, including those with severe symptoms.</p></div><span id="v46183692" class="anchor"></span><div class="para"> <p>In <b>patients with HFpEF,</b> beta-blockers have not shown clear benefits in clinical trials. However, data from large registries have suggested that beta-blocker use is associated with improved outcomes in HFpEF despite the relatively high prevalence of chronotropic incompetence (ie, the inability to raise heart rate in response to increased exertional demand) in HFpEF. All major <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183753" data-toggle="tooltip" title="Drug treatment references" data-id="f7943a07-d60c-49e4-b015-6f71b204d947" data-itemid="8421724d-323b-4c1e-a65f-97616ef1e639">guidelines for heart failure</a><span id="f7943a07-d60c-49e4-b015-6f71b204d947" class="d-none xref"> <span class="tooltip-container"> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183753"> <span class="tooltip-content"> <span class="tooltip-heading"> Drug treatment references </span> Heart failure (HF) is a syndrome of ventricular dysfunction (see Heart Failure). Drug treatment of heart failure (HF) involves symptom relief with Diuretics Nitrates Digoxin <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span> recommend beta-blockade as first-line therapy for conditions where ventricular rate control is indicated (ie, control of ventricular rate with atrial fibrillation). </p></div><span id="v46183693" class="anchor"></span><div class="para"> <p>The starting dose should be low (one fourth of the target daily dose), then the dose is gradually increased over 8 weeks as tolerated. The acute negative inotropic effects of beta-blockade may initially cause cardiac depression and fluid retention. In such cases, a temporary increase in diuretic dose and slower upward titration of the beta-blocker dose is warranted. Tolerance may improve over time, and efforts should be made to reach target doses. Usual oral target doses are <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>carvedilol</span> 25 mg twice a day (50 mg twice a day for patients <span class='symbol'>≥</span> 85 kg), <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>bisoprolol</span> 10 mg once a day, and <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>metoprolol</span> 50 to 75 mg twice a day (tartrate) or 200 mg once a day (succinate extended-release). <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Carvedilol</span>, a 3rd-generation nonselective beta-blocker, is also a vasodilator with alpha-blocking and antioxidant effects; it is the preferred and most widely studied beta-blocker but is more expensive in many countries. Some beta-blockers (eg, bucindolol, xamoterol) do not appear beneficial and may be harmful.</p></div><span id="v46183694" class="anchor"></span><div class="para"> <p>During a severe, acute decompensation, beta-blockers should not be started until patients are stabilized and have little evidence of fluid retention. For HFrEF patients with acute HF exacerbation already taking a beta-blocker, the dose should not be decreased or stopped unless absolutely necessary. Often the beta-blocker dose can be continued in patients with an acute HF exacerbation if the diuretic dose is temporarily increased.</p></div><span id="v46183695" class="anchor"></span><div class="para"> <p>In <b>HFrEF,</b> after initial treatment, heart rate and myocardial oxygen consumption decrease, and stroke volume and filling pressure are unchanged. With the slower heart rate, diastolic function improves. Ventricular filling returns to a more normal pattern (increasing in early diastole), which appears less restrictive. Improved myocardial function is measurable in some patients after 6 to 12 months but may take longer; ejection fraction (EF) and cardiac output (CO) increase, and LV filling pressure decreases. Exercise capacity improves.</p></div> </div> </section> <section id="v46183696" class="topic__section GHead"> <span></span> <h3 id="" class="topic__header--subsection"> <span id="v46183697" class="anchor"></span> Digoxin </h3> <div class="topic__content"> <span id="v46183698" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Digoxin</span> inhibits the sodium-potassium pump (Na+, K+-ATPase). As a result, it causes weak positive inotropy, reduces sympathetic activity, blocks the atrioventricular node (slowing the ventricular rate in atrial fibrillation or prolonging the PR interval in sinus rhythm), reduces vasoconstriction, and improves renal blood flow. <span class="genericDrug" data-showrollover="false">Digoxin</span> is excreted by the kidneys; elimination half-life is 36 to 40 hours in patients with normal renal function.</p></div><span id="v46183699" class="anchor"></span><div class="para"> <p><span class="genericDrug" data-showrollover="false">Digoxin</span> has no proven survival benefit but, when used with diuretics and an ACE inhibitor, may help control symptoms and reduce the likelihood of hospitalization in patients with HFrEF. However, because of the availability of a large number of evidence-based treatments for HFrEF, <span class="genericDrug" data-showrollover="false">digoxin</span> use has dropped significantly and is reserved for patients with significant symptoms despite optimal treatment with other mortality lowering medications. <span class="genericDrug" data-showrollover="false">Digoxin</span> should not be used in HFpEF unless it is being used to control heart rate in concomitant atrial fibrillation or to augment RV function in patients with RV failure. <span class="genericDrug" data-showrollover="false">Digoxin</span> is most effective in patients with large LV end-diastolic volumes and a 3rd heart sound (S3). Acute withdrawal of <span class="genericDrug" data-showrollover="false">digoxin</span> may increase the hospitalization rate and worsen symptoms. </p></div><span id="v46183700" class="anchor"></span><div class="para"> <p>In patients with normal renal function, <span class="genericDrug" data-showrollover="false">digoxin</span>, 0.125 to 0.25 mg orally once a day depending on age, sex, and body size, achieves full digitalization in about 1 week (5 half-lives). More rapid digitalization can be achieved with <span class="genericDrug" data-showrollover="false">digoxin</span> 0.5 mg IV over 15 minutes followed by 0.25 mg IV at 8 and 16 hours or with 0.5 mg orally followed by 0.25 mg orally at 8, 16, and 24 hours. Prescription patterns vary widely by physician and by country, but in general, doses are lower than those used in the past, and a trough (8- to 12-hours post-dose) <span class="genericDrug" data-showrollover="false">digoxin</span> level of 0.8 to 1.2 ng/mL (1 to 1.5 nmol/L) is preferable. In addition, unlike in the treatment of atrial fibrillation, there is typically little reason to rapidly digitalize (ie, <span class="genericDrug" data-showrollover="false">digoxin</span> load) patients with HF. Thus, simply starting <span class="genericDrug" data-showrollover="false">digoxin</span> at 0.125 mg orally once a day (in patients with normal renal function) or <span class="genericDrug" data-showrollover="false">digoxin</span> 0.125 mg orally every Monday, Wednesday, and Friday (in patients with abnormal renal function) is sufficient in patients with heart failure. </p></div><span id="v46183701" class="anchor"></span><div class="para"> <p><b><span class="genericDrug" data-showrollover="false">Digoxin</span> toxicity</b> is a concern, especially in patients with renal dysfunction and perhaps in women. These patients may need a lower oral dose, as may older patients, patients with a low lean body mass, and patients also taking <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>amiodarone</span>. <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Digoxin</span> has a narrow therapeutic window. The most important toxic effects are life-threatening arrhythmias (eg, <a href="./{861A5B4C-676D-40CB-9D96-7F6C96D693E4}.html" data-toggle="tooltip" title="Ventricular Fibrillation (VF)" data-id="c0d75644-a792-4aaf-8ffa-446f1b39b4d6" data-itemid="861a5b4c-676d-40cb-9d96-7f6c96d693e4">ventricular fibrillation</a><span id="c0d75644-a792-4aaf-8ffa-446f1b39b4d6" class="d-none xref"> <span class="tooltip-container"> <a href="./{861A5B4C-676D-40CB-9D96-7F6C96D693E4}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Ventricular Fibrillation (VF) </span> Ventricular fibrillation causes uncoordinated quivering of the ventricle with no useful contractions. It causes immediate syncope and death within minutes. Treatment is with cardiopulmonary... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/3/8/1/381_v_fib_slide_20_springer_high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Ventricular Fibrillation (VF)" loading="lazy"> </span> </a> </span> </span>, <a href="./{F3C3883E-2DE3-4D26-ABB0-E505584EECB4}.html" data-toggle="tooltip" title="Ventricular Tachycardia (VT)" data-id="3b5a482b-a3b5-45ee-a95a-7bc75b061510" data-itemid="f3c3883e-2de3-4d26-abb0-e505584eecb4">ventricular tachycardia</a><span id="3b5a482b-a3b5-45ee-a95a-7bc75b061510" class="d-none xref"> <span class="tooltip-container"> <a href="./{F3C3883E-2DE3-4D26-ABB0-E505584EECB4}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Ventricular Tachycardia (VT) </span> Ventricular tachycardia is ≥ 3 consecutive ventricular beats at a rate ≥ 120 beats/minute. Symptoms depend on duration and vary from none to palpitations to hemodynamic collapse and death. Diagnosis... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>, complete <a href="./{6DAA6064-7FA0-4A0C-B5A7-32DCC33D4B03}.html" data-toggle="tooltip" title="Atrioventricular Block" data-id="bdb2e2b2-e290-495e-bdca-e5e8a1623e7c" data-itemid="6daa6064-7fa0-4a0c-b5a7-32dcc33d4b03">atrioventricular block</a><span id="bdb2e2b2-e290-495e-bdca-e5e8a1623e7c" class="d-none xref"> <span class="tooltip-container"> <a href="./{6DAA6064-7FA0-4A0C-B5A7-32DCC33D4B03}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Atrioventricular Block </span> Atrioventricular (AV) block is partial or complete interruption of impulse transmission from the atria to the ventricles. The most common cause is idiopathic fibrosis and sclerosis of the conduction... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/o/b/mobitz-i-four-to-three-cropped-annotated-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Atrioventricular Block" loading="lazy"> </span> </a> </span> </span>). Bidirectional ventricular tachycardia, nonparoxysmal junctional tachycardia in the presence of atrial fibrillation, and hyperkalemia are serious signs of digitalis toxicity. Nausea, vomiting, anorexia, diarrhea, confusion, amblyopia, and, rarely, xerophthalmia may occur. If <a href="./{A426E3E7-CFA3-48BC-8257-C6CFB7BC8C23}.html" data-toggle="tooltip" title="Hypokalemia" data-id="e6ee33a1-c0dd-462a-9f12-9d2b79db1a5f" data-itemid="a426e3e7-cfa3-48bc-8257-c6cfb7bc8c23">hypokalemia</a><span id="e6ee33a1-c0dd-462a-9f12-9d2b79db1a5f" class="d-none xref"> <span class="tooltip-container"> <a href="./{A426E3E7-CFA3-48BC-8257-C6CFB7BC8C23}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Hypokalemia </span> Hypokalemia is serum potassium concentration < 3.5 mEq/L (< 3.5 mmol/L) caused by a deficit in total body potassium stores or abnormal movement of potassium into cells. The most common... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span> or <a href="./{274B74D5-B2C9-4C04-BE6E-F148FBD37762}.html" data-toggle="tooltip" title="Hypomagnesemia" data-id="8104e62f-179c-4f2c-8b03-008b6cea2751" data-itemid="274b74d5-b2c9-4c04-be6e-f148fbd37762">hypomagnesemia</a><span id="8104e62f-179c-4f2c-8b03-008b6cea2751" class="d-none xref"> <span class="tooltip-container"> <a href="./{274B74D5-B2C9-4C04-BE6E-F148FBD37762}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Hypomagnesemia </span> Hypomagnesemia is serum magnesium concentration < 1.8 mg/dL (< 0.70 mmol/L). Causes include inadequate magnesium intake and absorption or increased excretion due to hypercalcemia or medications... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span> (often due to diuretic use) is present, lower doses and serum levels can still cause toxicity. Electrolyte levels should be monitored in patients taking diuretics and <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>digoxin</span>, so that abnormalities can be prevented if possible; potassium-sparing diuretics may be helpful.</p></div><span id="v46183707" class="anchor"></span><div class="para"> <p>When <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>digoxin</span> toxicity occurs, the drug should be stopped; electrolyte abnormalities should be corrected (IV if abnormalities are severe and toxicity is acute). Patients with severe toxicity are admitted to a monitored unit, and <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>digoxin immune Fab</span> (ovine antidigoxin antibody fragments) is given if arrhythmias are present or if significant overingestion is accompanied by a serum potassium of <span class='symbol'>></span> 5 mEq/L (> 5 mmol/L). <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Digoxin immune Fab</span> is also useful for glycoside toxicity due to plant ingestion. Dose is based on the steady-state serum <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>digoxin</span> level or total amount ingested. Ventricular arrhythmias are treated with <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>lidocaine</span> or <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>phenytoin</span>. Atrioventricular block with a slow ventricular rate may require a temporary transvenous pacemaker. <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Isoproterenol</span> is contraindicated because it increases risk of ventricular arrhythmia.</p></div> </div> </section> <section id="v46183708" class="topic__section GHead"> <span></span> <h3 id="" class="topic__header--subsection"> <span id="v46183709" class="anchor"></span> Diuretics </h3> <div class="topic__content"> <span id="v46183710" class="anchor"></span><div class="para"> <p>Diuretics are given to all patients with HF (regardless of underlying ejection fraction) who have current or previous volume overload; dose is adjusted to the lowest dose that stabilizes weight and relieves symptoms. </p></div><span id="v46183711" class="anchor"></span><div class="para"> <p><b>Loop diuretics</b> should be used initially for control of volume overload, but their dose should be reduced when possible in favor of <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183648" data-toggle="tooltip" title="Aldosterone antagonists" data-id="201b2692-59d5-4700-b5a1-513cd69f77e6" data-itemid="8421724d-323b-4c1e-a65f-97616ef1e639">aldosterone antagonists</a><span id="201b2692-59d5-4700-b5a1-513cd69f77e6" class="d-none xref"> <span class="tooltip-container"> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183648"> <span class="tooltip-content"> <span class="tooltip-heading"> Aldosterone antagonists </span> Heart failure (HF) is a syndrome of ventricular dysfunction (see Heart Failure). Drug treatment of heart failure (HF) involves symptom relief with Diuretics Nitrates Digoxin <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>. </p></div><span id="v46183713" class="anchor"></span><div class="para"> <p>Commonly used loop diuretics include <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>furosemide</span>, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>bumetanide</span>, and <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>torsemide</span>. The starting dose of these drugs depends on whether the patient has previously received loop diuretics. Common starting doses are: <span class="genericDrug" data-showrollover="false">furosemide</span> 20 to 40 mg orally once a day or twice a day, <span class="genericDrug" data-showrollover="false">bumetanide</span> 0.5 to 1.0 mg orally once a day, and <span class="genericDrug" data-showrollover="false">torsemide</span> 10 to 20 mg orally once a day. If needed, loop diuretics can be titrated up to doses of <span class="genericDrug" data-showrollover="false">furosemide</span> 120 mg orally twice a day, <span class="genericDrug" data-showrollover="false">bumetanide</span> 2 mg orally twice a day, and <span class="genericDrug" data-showrollover="false">torsemide</span> 40 mg orally twice a day based on response and renal function. <span class="genericDrug" data-showrollover="false">Bumetanide</span> and <span class="genericDrug" data-showrollover="false">torsemide</span> have better bioavailability than <span class="genericDrug" data-showrollover="false">furosemide</span>. If patients are switched between different loop diuretics, they should be placed on equivalent doses. <span class="genericDrug" data-showrollover="false">Furosemide</span> 40 mg is equivalent to <span class="genericDrug" data-showrollover="false">bumetanide</span> 1 mg, and both are equivalent to <span class="genericDrug" data-showrollover="false">torsemide</span> 20 mg. </p></div><span id="v46183714" class="anchor"></span><div class="para"> <p>In refractory cases, IV loop diuretics or <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>metolazone</span> 2.5 to 10 mg orally can be used for an additive effect. IV infusion of <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>furosemide</span> (5 to 10 mg/hour) or other loop diuretics may be helpful in selected patients with severe edema. A bolus dose of loop diuretic should be given before starting an IV infusion and before each increase in infusion rate. </p></div><span id="v46183715" class="anchor"></span><div class="para"> <p>Loop diuretics (particularly when used with <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>metolazone</span>) may cause hypovolemia with hypotension, hyponatremia, hypomagnesemia, and severe hypokalemia. The dose of diuretic required acutely can usually be gradually reduced; the target is the lowest dose that maintains stable weight and controls symptoms. When HF improves, the diuretic may be stopped if other drugs improve heart function and relieve HF symptoms. Using larger than required doses of diuretics lowers CO, impairs renal function, causes hypokalemia, and increases mortality. Serum electrolytes and renal function are monitored, initially daily (when diuretics are given IV) and subsequently as needed, particularly after a dose increase.</p></div><span id="v46183716" class="anchor"></span><div class="para"> <p>An <b>aldosterone antagonist,</b> either <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>spironolactone</span> or <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>eplerenone</span>, should be added early to offset the potassium-losing effects of higher-dose loop diuretics. Hyperkalemia may result, especially when ACE inhibitors or ARBs are also taken, so electrolytes must still be monitored, especially during a dehydrating illness that could cause renal dysfunction. Aldosterone antagonists may have particular benefit in chronic right ventricular failure, in which hepatic congestion results in elevated aldosterone levels as aldosterone metabolism is reduced. To reduce the risk of hyperkalemia, aldosterone antagonists should generally be given only to patients whose potassium level is < 5.0 mEq/L (< 5 mmol/L), serum creatinine is < 2.5 mg/dL (< 221 micromol/L), and GFR is > 30 mL/min/1.73 m<sup>2</sup>. Furthermore, it should be noted that the equivalent dose of <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>eplerenone</span> is twice that of <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>spironolactone</span> (ie, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>spironolactone</span> 25 mg = <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>eplerenone</span> 50 mg). </p></div><span id="v46183717" class="anchor"></span><div class="para"> <p><b>Thiazide diuretics</b> are not normally used alone unless being given as treatment of hypertension; however, a thiazide diuretic may be added to a loop diuretic for additional diuresis and to reduce the loop diuretic dose. <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Hydrochlorothiazide</span>, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>metolazone</span>, and <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>chlorthalidone</span> can be used in this manner.</p></div><span id="v46183718" class="anchor"></span><div class="para"> <p>Reliable patients are taught to take additional diuretic doses as needed when weight or peripheral edema increases. They should seek medical attention promptly if weight gain persists.</p></div><span id="v46183719" class="anchor"></span><div class="para"> <p><span class="genericDrug" data-showrollover="false">Vasopressin</span> (antidiuretic hormone) receptor antagonists are not frequently used though they may be helpful in cases of severe refractory hyponatremia in patients with HF.</p></div> </div> </section> <section id="v46183721" class="topic__section GHead"> <span></span> <h3 id="" class="topic__header--subsection"> <span id="v46183722" class="anchor"></span> Sinus node inhibitors </h3> <div class="topic__content"> <span id="v46183723" class="anchor"></span><div class="para"> <p>There is an inward sodium/potassium current that travels through a certain gated channel (funny or "f" channel) in sinus node (cardiac pacemaker) cells located in the posterior right atrium. This current is sometimes referred to as the inward funny current (I<sub>f</sub>). Inhibition of this current prolongs the time it takes to achieve critical spontaneous depolarization of pacemaker cells, and thus lowers the heart rate.</p></div><span id="v46183724" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Ivabradine</span> is an I<sub>f</sub> channel blocker that acts at the sinus node to slow the heart rate. Since the receptors are present only in cardiac pacemaker cells, these drugs have no other cardiac effects (ie they do not directly affect contractility), and are not useful for treatment in patients who are not in sinus rhythm. <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Ivabradine</span> is currently recommended for use in HFrEF patients who have symptomatic HF, normal sinus rhythm, and heart rate > 70 beats/minute despite guideline-directed medical therapy (which should include beta-blockers). Typically, patients who may benefit from <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>ivabradine</span> are those with HFrEF who have NYHA (New York Heart Association) class II or class III symptoms (see table <span class="multimedia__link mlinkBlock" data-bind="component: { name: 'm-link-text', params: $data }" data-popup-model='{"ItemId":"1eb88a9a-a642-4893-be34-e8ce67f84ade","Title":"New%20York%20Heart%20Association%20%28NYHA%29%20Classification%20of%20Heart%20Failure","ShareUrlTitle":"new-york-heart-association-nyha-classification-of-heart-failure","Description":"","ImageUrl":null,"ThumbnailUrl":"/Content/Images/Redesign/table/icon_table_red.png","MediaType":"table","MediaNameTranslated":"Table","UniqueId":"v936085","Placement":null,"IsInCarousel":false,"Edition":0,"ImageWidth":null,"ImageHeight":null,"IframeSrc":null,"Target":null,"Alt":null}' data-popup-options='{"ListName":"TopicMultimedia","LinkText":"%3Cspan%20%3ENYHA%20Classification%20of%20Heart%20Failure%3C%2Fspan%3E","CssClass":null,"LoadLocations":true,"ShowTooltip":true,"SingleItem":true,"ExcludeFromBrand":"","ShowCredits":true,"ShowDescription":true,"PopupTitle":"Table","ShowTitle":true,"ShowIcon":false,"ShowModalIndicator":false,"ShowTitleInHeader":false,"HideCarousel":false,"Target":"modal","Url":null,"HideMainArrows":false}'></span>) and heart rate > 70 beats/minute who are at target beta-blocker dose or cannot tolerate a further increase in beta-blocker dose (<a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183753" data-toggle="tooltip" title="Drug treatment references" data-id="b37e38d6-73fa-4c1e-9628-70a493bcfa81" data-itemid="8421724d-323b-4c1e-a65f-97616ef1e639">8</a><span id="b37e38d6-73fa-4c1e-9628-70a493bcfa81" class="d-none xref"> <span class="tooltip-container"> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183753"> <span class="tooltip-content"> <span class="tooltip-heading"> Drug treatment references </span> Heart failure (HF) is a syndrome of ventricular dysfunction (see Heart Failure). Drug treatment of heart failure (HF) involves symptom relief with Diuretics Nitrates Digoxin <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>).</p></div><span id="v46183726" class="anchor"></span><div class="para"> <p>Initial dose of <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>ivabradine</span> is 2.5 to 5 mg orally twice a day, titrated at 2-week intervals to a heart rate of 50 to 60 beats/minute; maximum dose is 7.5 mg twice a day. </p></div><span id="v46183727" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Ivabradine</span> is currently the only drug in this class.</p></div> </div> </section> <section id="v46183728" class="topic__section GHead"> <span></span> <h3 id="" class="topic__header--subsection"> <span id="v46183729" class="anchor"></span> Sodium-glucose cotransporter-2 inhibitors (SGLT2i) </h3> <div class="topic__content"> <span id="v46183730" class="anchor"></span><div class="para"> <p>SGLT2 inhibitors are used in treatment of diabetes to block glucose reabsorption, thus causing glycosuria and lowering plasma glucose. They may also have effects on the myocardium and vasculature. These drugs had previously been shown to prevent the onset of heart failure in patients with type 2 diabetes. One member of this class, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>dapagliflozin</span>, was shown to improve symptoms and quality of life and decrease hospitalization and mortality in patients with HFrEF when added to standard care in patients with elevated natriuretic peptide levels; benefit was similar in patients with and without diabetes (<a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183753" data-toggle="tooltip" title="Drug treatment references" data-id="dafe3f94-bd96-4bf9-92f2-a85d8176ccce" data-itemid="8421724d-323b-4c1e-a65f-97616ef1e639">9</a><span id="dafe3f94-bd96-4bf9-92f2-a85d8176ccce" class="d-none xref"> <span class="tooltip-container"> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183753"> <span class="tooltip-content"> <span class="tooltip-heading"> Drug treatment references </span> Heart failure (HF) is a syndrome of ventricular dysfunction (see Heart Failure). Drug treatment of heart failure (HF) involves symptom relief with Diuretics Nitrates Digoxin <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>). In a recent clinical trial, the addition of the SGLT2 inhibitor <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>empagliflozin</span> to usual therapy was shown to reduce hospitalizations and death for patients with HFpEF, with or without diabetes (<a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183753" data-toggle="tooltip" title="Drug treatment references" data-id="c81ba49d-241d-4485-a033-558f61328a19" data-itemid="8421724d-323b-4c1e-a65f-97616ef1e639">10</a><span id="c81ba49d-241d-4485-a033-558f61328a19" class="d-none xref"> <span class="tooltip-container"> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183753"> <span class="tooltip-content"> <span class="tooltip-heading"> Drug treatment references </span> Heart failure (HF) is a syndrome of ventricular dysfunction (see Heart Failure). Drug treatment of heart failure (HF) involves symptom relief with Diuretics Nitrates Digoxin <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>). </p></div><span id="v46183731" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Dapagliflozin</span> and <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>empagliflozin</span> may be given 10 mg orally once a day. With treatment, there is a mild (10 to 15%) reduction in estimated glomerular filtration rate (eGFR) which does not progress, glucosuria, and a small reduction in body weight. Risks include genital fungal infection, and in patients with diabetes, a very small risk of hypoglycemia and diabetic ketoacidosis. These drugs are generally not indicated in patients with type I diabetes, low blood pressure, low eGFR (< 30 mL/min/1.73 m<sup>2</sup>), or rapidly worsening renal function.</p></div><span id="v46183732" class="anchor"></span><div class="para"> <p>Other SGLT2 inhibitors (eg, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>canagliflozin</span>, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>ertugliflozin</span>) have not been studied directly in HF, but secondary analysis of studies in diabetes suggest they may also be beneficial.</p></div> </div> </section> <section id="v46183733" class="topic__section GHead"> <span></span> <h3 id="" class="topic__header--subsection"> <span id="v46183734" class="anchor"></span> Vasodilators </h3> <div class="topic__content"> <span id="v46183735" class="anchor"></span><div class="para"> <p><b><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Hydralazine</span> plus <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>isosorbide dinitrate</span></b> may help patients truly intolerant of ACE inhibitors or ARBs (usually because of significant renal dysfunction), although limited studies show long-term benefit of this combination. However, in patients of African ancestry this combination, when added to standard therapy, has been shown to reduce mortality and hospitalization, and improve quality of life. As vasodilators, these drugs improve hemodynamics, reduce valvular regurgitation, and increase exercise capacity without causing significant renal impairment. </p></div><span id="v46183736" class="anchor"></span><div class="para"> <p>When used instead of ACE/ARB therapy, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>hydralazine</span> is started at 25 mg orally 4 times a day and increased every 3 to 5 days to a target total dose of 300 mg/day, although many patients cannot tolerate <span class='symbol'>></span> 200 mg/day because of hypotension. <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Isosorbide dinitrate</span> is started at 20 mg orally 3 times a day (with a 12-hour nitrate-free interval) and increased to a target of 40 to 50 mg 3 times a day. Whether lower doses (frequently used in clinical practice) provide long-term benefit is unknown. In general, vasodilators have been replaced by ACE inhibitors, which are easier to use, are usually better tolerated, and have greater proven benefit.</p></div><span id="v46183737" class="anchor"></span><div class="para"> <p>When added to ACE/ARB therapy, <span class="genericDrug" data-showrollover="false">hydralazine</span>-nitrate therapy may benefit patients of African ancestry with HFrEF. In this case, the starting dose is <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>hydralazine</span> 37.5 mg and <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>isosorbide dinitrate</span> 20 mg orally three times a day, with the maximum dose 75 mg and 40 mg three times a day. These doses are also available as a fixed-dose combination. The decision to add or substitute <span class="genericDrug" data-showrollover="false">hydralazine</span>-nitrate therapy to an ACE/ARB in patients of African ancestry with HF is patient specific and frequently determined by drug tolerance and symptom burden. In general, RAAS inhibitor therapy (ACE, ARB, or ARNI) should be used in this population, if tolerated.</p></div><span id="v46183738" class="anchor"></span><div class="para"> <p>Nitrates alone can relieve HF symptoms in patients with HFrEF; patients can be taught to use sublingual <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>nitroglycerin</span> spray as needed for acute dyspnea and a transdermal patch for nocturnal or exertional dyspnea. In HFrEF, nitrates are safe, effective, and well tolerated and are particularly helpful in patients with HF and <a href="./{EAD663A1-8F93-4B72-881E-2BCEFEC7B069}.html" data-toggle="tooltip" title="Angina Pectoris" data-id="41c9f699-25f0-4595-86db-828c709743a5" data-itemid="ead663a1-8f93-4b72-881e-2bcefec7b069">angina</a><span id="41c9f699-25f0-4595-86db-828c709743a5" class="d-none xref"> <span class="tooltip-container"> <a href="./{EAD663A1-8F93-4B72-881E-2BCEFEC7B069}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Angina Pectoris </span> Angina pectoris is a clinical syndrome of precordial discomfort or pressure due to transient myocardial ischemia without infarction. It is typically precipitated by exertion or psychologic stress... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>. Adverse effects include hypotension and headache. <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Isosorbide mononitrate</span> has been tested in HFpEF (<a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183753" data-toggle="tooltip" title="Drug treatment references" data-id="368f1181-43fa-4bee-9371-e95f3c826e05" data-itemid="8421724d-323b-4c1e-a65f-97616ef1e639">11</a><span id="368f1181-43fa-4bee-9371-e95f3c826e05" class="d-none xref"> <span class="tooltip-container"> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183753"> <span class="tooltip-content"> <span class="tooltip-heading"> Drug treatment references </span> Heart failure (HF) is a syndrome of ventricular dysfunction (see Heart Failure). Drug treatment of heart failure (HF) involves symptom relief with Diuretics Nitrates Digoxin <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>), where it was shown to be associated with increased adverse effects (eg, headache) and reduced physical activity. Thus, routine use of long-acting nitrates should be avoided in HFpEF.</p></div><span id="v46183741" class="anchor"></span><div class="para"> <p>Other vasodilators such as calcium channel blockers are not used to treat LV systolic dysfunction. Short-acting dihydropyridines (eg, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>nifedipine</span>) and nondihydropyridines (eg, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>diltiazem</span>, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>verapamil</span>) may be deleterious. However, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>amlodipine</span> and <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>felodipine</span> are better tolerated and may be useful for patients with HF and associated angina or <a href="./{B9A25E4F-9BEA-42DE-8EE8-16E867ADC0B5}.html" data-toggle="tooltip" title="Hypertension" data-id="707cc2c2-1ba1-4d55-bdc6-6133d8a62111" data-itemid="b9a25e4f-9bea-42de-8ee8-16e867adc0b5">hypertension</a><span id="707cc2c2-1ba1-4d55-bdc6-6133d8a62111" class="d-none xref"> <span class="tooltip-container"> <a href="./{B9A25E4F-9BEA-42DE-8EE8-16E867ADC0B5}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Hypertension </span> Hypertension is sustained elevation of resting systolic blood pressure (≥ 130 mm Hg), diastolic blood pressure (≥ 80 mm Hg), or both. Hypertension with no known cause (primary; formerly, essential... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/5/1/5/515-left-ventricular-hypertrophy-on-ekg-s108-springer-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Hypertension" loading="lazy"> </span> </a> </span> </span>. Both drugs may cause peripheral edema; rarely, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>amlodipine</span> causes <a href="./{506AFC9F-5EFE-4824-892F-9DBA78FB80CD}.html" data-toggle="tooltip" title="Pulmonary Edema" data-id="2eea6ad5-ea0b-4e51-98cb-60dd0294b471" data-itemid="506afc9f-5efe-4824-892f-9dba78fb80cd">pulmonary edema</a><span id="2eea6ad5-ea0b-4e51-98cb-60dd0294b471" class="d-none xref"> <span class="tooltip-container"> <a href="./{506AFC9F-5EFE-4824-892F-9DBA78FB80CD}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Pulmonary Edema </span> Pulmonary edema is acute, severe left ventricular failure with pulmonary venous hypertension and alveolar flooding. Findings are severe dyspnea, diaphoresis, wheezing, and sometimes blood-tinged... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/3/7/n/37-new-chest-xray-of-patient-pulmonary-edema-ctisus.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Pulmonary Edema" loading="lazy"> </span> </a> </span> </span>. <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Felodipine</span> should not be taken with grapefruit juice, which significantly increases plasma levels and adverse effects by inhibiting cytochrome P-450 metabolism. In patients with HFpEF, dihydropyridine calcium channel blockers such as <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>amlodipine</span> may be used as needed to treat hypertension or ischemia; nondihydropyridines such as <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>diltiazem</span> or <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>verapamil</span> may be used to control ventricular rate in <a href="./{3118C057-FB1F-4AA1-8B87-C346CBC408C3}.html" data-toggle="tooltip" title="Atrial Fibrillation" data-id="7975ad76-8740-4e83-9464-2fc3210368c4" data-itemid="3118c057-fb1f-4aa1-8b87-c346cbc408c3">atrial fibrillation</a><span id="7975ad76-8740-4e83-9464-2fc3210368c4" class="d-none xref"> <span class="tooltip-container"> <a href="./{3118C057-FB1F-4AA1-8B87-C346CBC408C3}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Atrial Fibrillation </span> Atrial fibrillation is a rapid, irregularly irregular atrial rhythm. Symptoms include palpitations and sometimes weakness, effort intolerance, dyspnea, and presyncope. Atrial thrombi may form... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>. <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Verapamil</span> is often used in <a href="./{BCB4C7FA-246E-4116-8AD2-049B1C4F4B42}.html" data-toggle="tooltip" title="Hypertrophic Cardiomyopathy" data-id="dbbd0e85-f5c2-44cd-930d-9be9b2b4813a" data-itemid="bcb4c7fa-246e-4116-8ad2-049b1c4f4b42">hypertrophic cardiomyopathy</a><span id="dbbd0e85-f5c2-44cd-930d-9be9b2b4813a" class="d-none xref"> <span class="tooltip-container"> <a href="./{BCB4C7FA-246E-4116-8AD2-049B1C4F4B42}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Hypertrophic Cardiomyopathy </span> Hypertrophic cardiomyopathy is a congenital or acquired disorder characterized by marked ventricular hypertrophy with diastolic dysfunction (eg, due to valvular aortic stenosis, coarctation... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/1/1/c/11-cardiac-mri-showing-hypertrophic-cardiomypathy-ctisus.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Hypertrophic Cardiomyopathy" loading="lazy"> </span> </a> </span> </span>.</p></div> </div> </section> <section id="v46183746" class="topic__section GHead"> <span></span> <h3 id="" class="topic__header--subsection"> <span id="v46183747" class="anchor"></span> Other drugs </h3> <div class="topic__content"> <span id="v46183748" class="anchor"></span><div class="para"> <p>Various <b>positive inotropic drugs</b> have been evaluated in heart failure but, except for <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>digoxin</span>, they increase mortality risk. These drugs can be grouped as adrenergic mode of action (<span class="genericDrug" data-showrollover="false">norepinephrine</span>, <span class="genericDrug" data-showrollover="false">epinephrine</span>, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>dobutamine</span>, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>dopamine</span>) or nonadrenergic (enoximone, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>milrinone</span>, levosimendan [calcium sensitizers]). Regular outpatient IV infusions of inotropes (eg, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>dobutamine</span>) were previously tried but found to increase mortality and are not recommended. However, outpatient continuous infusions of inotropes such as <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>dobutamine</span> or <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>milrinone</span> can be used for palliative purposes in patients with severe HFrEF. </p></div><span id="v50500261" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Vericiguat</span> is an oral soluble guanylate cyclase stimulator which enhances the cyclic guanosine monophosphate (GMP) pathway and sensitizes soluble guanylate cyclase to endogenous nitric oxide, resulting in pulmonary vasodilation. A clinical trial in symptomatic chronic HFrEF patients with evidence of worsening HF demonstrated reduced cardiovascular mortality or HF hospitalizations for patients randomized to receive <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>vericiguat</span> (<a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183753" data-toggle="tooltip" title="Drug treatment references" data-id="49671fd3-cbd3-4680-a209-a881fd180326" data-itemid="8421724d-323b-4c1e-a65f-97616ef1e639">12</a><span id="49671fd3-cbd3-4680-a209-a881fd180326" class="d-none xref"> <span class="tooltip-container"> <a href="./{8421724D-323B-4C1E-A65F-97616EF1E639}.html#v46183753"> <span class="tooltip-content"> <span class="tooltip-heading"> Drug treatment references </span> Heart failure (HF) is a syndrome of ventricular dysfunction (see Heart Failure). Drug treatment of heart failure (HF) involves symptom relief with Diuretics Nitrates Digoxin <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>). <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Vericiguat</span> may therefore be an option to improve outcomes for HFrEF patients with worsening HF symptoms.</p></div> </div> </section> <section id="v46183752" class="topic__section GHead"> <span></span> <h3 id="" class="topic__header--subsection"> <span id="v46183753" class="anchor"></span> Drug treatment references </h3> <div class="topic__content"> <div class="list"> <ul data-mmanualobjecttype="List" class="nobulleted"><li class="topic__listitem"><span id="v46183756" class="anchor"></span><div class="para"> <p>1. <a rel="nofollow" target="_blank" href="https://pubmed.ncbi.nlm.nih.gov/24716680/">Pitt B, Pfeffer MA, Assmann SF, et al</a>: <span class="genericDrug" data-showrollover="false">Spironolactone</span> for heart failure with preserved ejection fraction. <i>N Engl J Med</i> 370:1383–1392, 2014. doi: 10.1056/NEJMoa1313731</p></div></li><li class="topic__listitem"><span id="v46183760" class="anchor"></span><div class="para"> <p>2. <a rel="nofollow" target="_blank" href="https://www.ncbi.nlm.nih.gov/pubmed/16963472">Cleland JG, Tendera M, Adamus J, et al</a>: The <span class="genericDrug" data-showrollover="false">perindopril</span> in elderly people with chronic heart failure (PEP-CHF) study. <i>Eur Heart J</i> 27:2338–2345, 2006. doi: 10.1093/eurheartj/ehl250</p></div></li><li class="topic__listitem"><span id="v46183764" class="anchor"></span><div class="para"> <p>3. <a rel="nofollow" target="_blank" href="https://www.ncbi.nlm.nih.gov/pubmed/13678871">Yusuf S, Pfeffer MA, Swedberg K, et al</a>: Effects of <span class="genericDrug" data-showrollover="false">candesartan</span> in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. <i>Lancet</i> 362:777, 2003. doi: 10.1016/S0140-6736(03)14285-7</p></div></li><li class="topic__listitem"><span id="v46183768" class="anchor"></span><div class="para"> <p>4. <a rel="nofollow" target="_blank" href="https://pubmed.ncbi.nlm.nih.gov/19001508/">Massie BM, Carson PE, McMurray JJ, et al</a>: <span class="genericDrug" data-showrollover="false">Irbesartan</span> in patients with heart failure and preserved ejection fraction. <i>N Engl J Med</i> 359:2456–2467, 2008. doi: 10.1056/NEJMoa0805450 </p></div></li><li class="topic__listitem"><span id="v46183772" class="anchor"></span><div class="para"> <p>5. <a rel="nofollow" target="_blank" href="https://pubmed.ncbi.nlm.nih.gov/25176015/">McMurray JJ, Packer M, Desai AS, et al</a>: Angiotensin-neprilysin inhibition versus <span class="genericDrug" data-showrollover="false">enalapril</span> in heart failure. <i>N Engl J Med</i> 371:993–1004, 2014. doi: 10.1056/NEJMoa1409077</p></div></li><li class="topic__listitem"><span id="v46183776" class="anchor"></span><div class="para"> <p>6. <a rel="nofollow" target="_blank" href="https://www.ncbi.nlm.nih.gov/pubmed/31475794">Solomon SD, McMurray JJ, Anand IS, et al</a>: Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. <i>N Engl J Med</i> 381:1609–1620, 2019. doi: 10.1056/NEJMoa1908655 </p></div></li><li class="topic__listitem"><span id="v46183780" class="anchor"></span><div class="para"> <p>7. <a rel="nofollow" target="_blank" href="https://www.ncbi.nlm.nih.gov/pubmed/31736337">McMurray JJV, Jackson AM, LAM CSP, et al</a>: Effects of <span class="genericDrug" data-showrollover="false">sacubitril</span>-<span class="genericDrug" data-showrollover="false">valsartan</span> Versus <span class="genericDrug" data-showrollover="false">valsartan</span> in women compared with men with heart failure and preserved ejection fraction: Insights From PARAGON-HF. <i>Circulation</i> 41(5):338–351, 2020. doi: 10.1161/CIRCULATIONAHA.119.044491</p></div></li><li class="topic__listitem"><span id="v50500266" class="anchor"></span><div class="para"> <p>8. <a rel="nofollow" target="_blank" href="https://pubmed.ncbi.nlm.nih.gov/20801500/">Swedberg K, Komajda M, Bohm M, et al</a>: <span class="genericDrug" data-showrollover="false">Ivabradine</span> and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. <i>Lancet</i> 376(9744):875–885, 2010. doi: 10.1016/S0140-6736(10)61198-1</p></div></li><li class="topic__listitem"><span id="v50500271" class="anchor"></span><div class="para"> <p>9. <a rel="nofollow" target="_blank" href="https://pubmed.ncbi.nlm.nih.gov/31535829/">McMurray JJV, Solomon SD, Inzucchi SE, et al</a>: <span class="genericDrug" data-showrollover="false">Dapagliflozin</span> in patients with heart failure and reduced ejection fraction. <i>N Engl J Med</i> 381(21):1995–2008, 2019. doi: 10.1056/NEJMoa1911303</p></div></li><li class="topic__listitem"><span id="v71486578" class="anchor"></span><div class="para"> <p>10. <a rel="nofollow" target="_blank" href="https://pubmed.ncbi.nlm.nih.gov/34449189/">Anker SD, Butler J, Filippatos G, et al</a>: <span class="genericDrug" data-showrollover="false">Empagliflozin</span> in heart failure with a preserved ejection fraction. <i>N Engl J Med</i> 385(16):1451-1461, 2021. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27. PMID: 34449189. </p></div></li><li class="topic__listitem"><span id="v46183783" class="anchor"></span><div class="para"> <p>11. <a rel="nofollow" target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1510774">Redfield M, Anstrom KJ, Levine JA, et al</a>: <span class="genericDrug" data-showrollover="false">Isosorbide mononitrate</span> in heart failure with preserved ejection fraction. <i>N Engl J Med</i> 373:2314–2324, 2015. doi: 10.1056/NEJMoa1510774</p></div></li><li class="topic__listitem"><span id="v50500276" class="anchor"></span><div class="para"> <p>12. <a rel="nofollow" target="_blank" href="https://pubmed.ncbi.nlm.nih.gov/32222134/">Armstrong PW, Pieske B, Anstrom KJ, et al</a>: <span class="genericDrug" data-showrollover="false">Vericiguat</span> in patients with heart failure and reduced ejection fraction. <i>N Engl J Med</i> 382(20):1883–1893, 2020. doi: 10.1056/NEJMoa1915928</p></div></li></ul></div> </div> </section> </div> </section> <section id="v50500280" class="topic__section FHead"> <h2 id="Further_v50500281" class="topic__header--section"> <span id="v50500281" class="anchor"></span> More Information </h2> <div class="topic__content"> <span id="v50500282" class="anchor"></span><div class="para"> <p>The following are some of the major English-language heart failure guidelines that may be useful. Please note that THE MANUAL is not responsible for the content of these resources.</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="nobulleted"><li class="topic__listitem"><span id="v71486583" class="anchor"></span><div class="para"> <p><a rel="nofollow" target="_blank" href="https://pubmed.ncbi.nlm.nih.gov/34447992/">McDonagh TA, Metra M, Adamo M, et al</a>: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. <i>Eur Heart J</i> 42(36):3599-3726, 2021. doi: 10.1093/eurheartj/ehab368 </p></div></li><li class="topic__listitem"><span id="v71486586" class="anchor"></span><div class="para"> <p><a rel="nofollow" target="_blank" href="https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000001062?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org">Heidenreich PA, Bozkurt B, Aguilar D, et al</a>: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> 145:e876–e894, 2022, doi: 10.1161/CIR.0000000000001062</p></div></li></ul></div> </div> </section>
 
 <section class="topic__section">
 <div class="topicswitch topic__patient-education topic__patient-education--bottom hide-on-print" data-icd9="MM1151">
 <div class="topic__patient-education--container">
 <div class="topic__patient-education--icon"></div>
 <div class="topic__patient-education--text">
 View PATIENT EDUCATION
 </div>
 </div>
 </div>
 </section>
</div>
<script type="text/javascript">
 $(document).ready(function () {
 $(document).on('click', '.topicswitch', function (e) {
 e.preventDefault();
 $.ajax({
 url: '/Custom/Edition/GetSwitchUrl',
 type: "GET",
 dataType: "json",
 data: {
 icd9: 'MM1151',
 title: 'Drugs for Heart Failure',
 itemGuid: '8421724d-323b-4c1e-a65f-97616ef1e639'
 }
 }).done(function (data) {
 
 // redirect
 location.href = data.href;
 }).fail(function (jqxhr, textStatus, errorThrown) {
 console.error(errorThrown);
 });
 });
 });
</script>
 </article>
 <div class="copyright-print">
 <div class="copyright-print--logo">
<img src="./Content/Images/msd_foot_logo.png" alt="" class="badge msd" loading="lazy" width="240" height="71">
 </div>
 <div class="copyright-print--text">
 Copyright © 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
 </div>
 </div>
 <section class="bottomnav__wrapper hide-on-print" style="display:none">
 
<div class="bottomnav no-print side-by-side">
 <div class="bottomnav__gotolink bottomnav__gotolink--previous">
 <a href="./{B4986CFA-B2A7-45D5-B89B-470DF0EAD991}.html">
 <div class="bottomnav__gotolink--content">
 <div class="bottomnav__icon bottomnav__icon--previous"></div>
 <div class="bottomnav__linktext">Heart Failure (HF)</div>
 </div>
 </a>
 </div>
 
 <div class="bottomnav__gotolink bottomnav__gotolink--next">
 <a href="./{506AFC9F-5EFE-4824-892F-9DBA78FB80CD}.html">
 <div class="bottomnav__gotolink--content">
 <div class="bottomnav__linktext">Pulmonary Edema</div>
 <div class="bottomnav__icon bottomnav__icon--next"></div>
 </div>
 </a>
 </div>
</div>
 </section>
</div>
<span id="showpopup"></span>
<span id="showchildpopup"></span>
<div class="box box--marketing marketing-block orderize__candidate hide-on-print" data-orderize="1301">
 <div class="marketing-block-wrapper">
 <div class="box__header">
 <div class="box__headertext"></div>
 </div>
 <div class="box__content">
<div class="marketingblock-quiz hide-on-print">
<div class="marketingblock-quiz-img">
<img alt="quiz link" src="./Content/Images/Redesign/quizzes_lightbulb_red.png" loading="lazy" width="64" height="52">
</div>
<div class="marketingblock-quiz-desc">
<h4>Test your knowledge</h4>
<a href="./{976709AA-1FDC-4953-8B32-2A9E9973AC21}.html">Take a Quiz! </a></div>
</div> </div>
 </div>
</div>
<script type="text/javascript">
 $('img[usemap]').rwdImageMaps();
</script>
<div class="box box--marketing marketing-block orderize__candidate hide-on-print" data-orderize="1550">
 <div class="marketing-block-wrapper">
 <div class="box__header">
 <div class="box__headertext"></div>
 </div>
 <div class="box__content">
 <div class="box__content--mobile">
 <img loading="lazy" src="./~/media/manual/marketing/mobileqr/en_msd_mobile_pro_326.gif" alt="" id="b574b412-2fe7-4e78-bd5e-97bdfc066662_mobile" usemap="#b574b412-2fe7-4e78-bd5e-97bdfc066662_mobile" width="326" height="90">
 <map name="b574b412-2fe7-4e78-bd5e-97bdfc066662_mobile">
 <area shape="RECT" coords="176,79,90,53" href="https://play.google.com/store/apps/details?id=com.msd.professional&referrer=utm_source%3DMMWeb%26utm_medium%3Dbanner%26utm_content%3DTopic1Vertical%26utm_campaign%3DWebAppAds" target="_blank" alt="iOS">
<area shape="RECT" coords="202,51,297,80" href="https://apps.apple.com/app/msd-professional-version/id1123678257" target="_blank" alt="ANDROID">
 </map>
 </div>
 <div class="box__content--tablet">
 <img loading="lazy" src="./~/media/manual/marketing/mobileqr/en_msd_mobile_pro_326.gif" alt="" id="b574b412-2fe7-4e78-bd5e-97bdfc066662_tablet" usemap="#b574b412-2fe7-4e78-bd5e-97bdfc066662_tablet" width="326" height="90">
 <map name="b574b412-2fe7-4e78-bd5e-97bdfc066662_tablet">
 <area shape="RECT" coords="176,79,90,53" href="https://play.google.com/store/apps/details?id=com.msd.professional&referrer=utm_source%3DMMWeb%26utm_medium%3Dbanner%26utm_content%3DTopic1Vertical%26utm_campaign%3DWebAppAds" target="_blank" alt="iOS">
<area shape="RECT" coords="202,51,297,80" href="https://apps.apple.com/app/msd-professional-version/id1123678257" target="_blank" alt="ANDROID">
 </map>
 </div>
 <div class="box__content--desktop">
 <img loading="lazy" src="./~/media/manual/marketing/mobileqr/en_msd_mobile_qr_pro_326.gif" alt="" id="b574b412-2fe7-4e78-bd5e-97bdfc066662_desktop" usemap="#b574b412-2fe7-4e78-bd5e-97bdfc066662_desktop" width="326" height="90">
 <map name="b574b412-2fe7-4e78-bd5e-97bdfc066662_desktop">
 <area shape="RECT" coords="176,79,90,53" href="https://apps.apple.com/app/msd-professional-version/id1123678257" target="_blank" alt="iOS">
<area shape="RECT" coords="202,51,297,80" href="https://play.google.com/store/apps/details?id=com.msd.professional&referrer=utm_source%3DMMWeb%26utm_medium%3Dbanner%26utm_content%3DTopic1Vertical%26utm_campaign%3DWebAppAds" target="_blank" alt="ANDROID">
 </map>
 </div>
 </div>
 </div>
</div>
<script type="text/javascript">
 $('img[usemap]').rwdImageMaps();
</script>
<a id="autoload" role="button" tabindex="-1"></a>
 <div class="autoload-placeholder hide-on-print" name="Up Next:"></div>
 <a class="next-topic hide-on-print" role="button" aria-hidden="true"></a>
 </div>
</div>
 </section>
 
 </main>
 
 <div class="l-layer l-layer--topscroll">
 <div class="topscroll topscroll--hidden">
 <div class="topscroll__container">
 <div class="topscroll__button">
 <div class="topscroll__content">
 <i class="topscroll__arrow"></i>
 TOP
 </div>
 </div>
 </div>
 <div class="topscroll__bar"></div>
</div>
 </div>
 </div>
 
 <div class="flyout hide-on-print" tabindex="0">
 <nav class="flyout__menu" role="application" aria-label="Menu">
 </nav>
 </div>
 <div class="print">
 <div id="print__content">
 </div>
 </div>
 <div class="multimedia__popup l-viewport" data-bind="component: { name: 'multimedia-popup'}">
 <!-- Placeholder for media players. -->
</div>
 <script type="text/javascript">
 //global value for translating the 'Read More' value
 var MMReadMore = "read more";
 var MMMaxTeaseCount = 250;
 </script>
 
 
<div class="sticky-footer hide-on-print">
 <ul>
 <li class="sticky-footer--topic">
 <button aria-label="Topic" class="sticky-footer-topicmenu" aria-expanded="false">
 <span class="footer-bar__icon topic-ico"></span>
 </button>
 <div class="footer-expand-cont footer-parent-cont topicList">
 <button aria-label="close" class="footer-expand-cont__close"></button>
 <div class="footer-topicList-wrapper">
 <div class="in-this-topic-sidebar">
 <div class="box__header">
 <span>IN THIS TOPIC</span>
 <span class="in-this-topic-togggle-btn" aria-label="IN THIS TOPIC" aria-expanded="false"></span>
 </div>
 </div>
 </div>
 </div>
 </li>
 <li class="sticky-footer--version-switcher nontopicpage">
 <a data-id="HE" href="/home" target="_self" aria-label="Version Switch">
 <span class="footer-bar__icon versionSwitcher-ico"></span>
 </a>
 </li>
 <li class="sticky-footer--version-switcher topicpage">
 <a class="topicswitch" href="#" target="_self" aria-label="Version Switch">
 <span class="footer-bar__icon versionSwitcher-ico"></span>
 </a>
 </li>
 <li class="sticky-footer--vetFilter"></li>
 <li>
 <a href="./{218352E5-01E6-4C81-9542-33CF998B22E9}.html" target="_self" aria-label="Resources">
 <span class="footer-bar__icon resources-ico"></span>
 </a>
 </li>
 <li class="sticky-footer--social">
 <aside class="actiontoolbar hide-on-print">
 <!--<a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--bookmark" onclick="bookmarkPage(this);" href="#"></a>-->
 <a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--download" style="display: none" href="#"></a>
 
 <ul>
 <li class="a2a_kit a2a_kit_size_32 a2a_default_style" data-a2a-icon-color="transparent,transparent">
 <a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--share a2a_dd" href="https://www.addtoany.com/share" rel="noopener" role="button" aria-expanded="false" aria-label="Share in"></a>
 </li>
 <li>
 <a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--print" href="#" onclick="window.print(); MManual.analytics.notifyOpenModal(MManual.analytics.eventPrintAnArticle);" role="button" title="print"></a>
 </li>
 <li class="a2a_kit a2a_kit_size_32 a2a_default_style" data-a2a-icon-color="transparent,transparent">
 <a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--email a2a_button_email" href="#" role="button" title="Mail"></a>
 </li>
 <li class="scroll-to-top">
 <a href="#top" role="button" aria-label="Go To Top" title="Go To Top"><span class="scroll-to-top-img"></span></a>
 </li>
 <li class="scroll-to-bottom">
 <a href="#" role="button" aria-label="Go To Top"><span class="scroll-to-bottom-img"></span></a>
 </li>
 </ul>
 </aside>
 </li>
 <li class="sticky-footer--moreCont">
 <button aria-label="More" class="sticky-footer--more" aria-expanded="false">
 <span class="footer-bar__icon more-ico"></span>
 </button>
 <div class="footer-expand-cont more-footer-container">
 <ul>
 <li>
 <a href="./{F01A9F26-96C0-45E2-8ACC-403ACDB78022}.html" target="_self" aria-label="Home">
 <span class="footer-bar__icon home-ico"></span>
 </a>
 </li>
 <li>
 <a href="./{FF41B506-E267-4A7F-8357-F8C0474115E2}.html" target="_self" aria-label="info">
 <span class="footer-bar__icon info-ico"></span>
 </a>
 </li>
 <li>
 <button aria-label="Settings" aria-expanded="false">
 <span class="footer-bar__icon settings-ico"></span>
 </button>
 <div class="footer-sub-cont settings-footer-cont"></div>
 </li>
 <li class="language-footer">
 <button aria-label="Select Language" aria-expanded="false">
 <span class="footer-bar__icon language-ico"></span>
 </button>
 <div class="footer-sub-cont language-footer-cont"></div>
 </li>
 </ul>
 </div>
 </li>
 </ul>
</div>
 
 
 
<!--[if (gte IE 9)|!(IE)]><!-->
<script type="text/javascript">
 function downloadJSAtOnload() {
 
 MManual.deferredScripts.push("./bundles/redesign/libsdeferredjsv4.1.2.2-13178e13ca.js?v=0HKp-yFnKaDEueCLP27J6D4rHb3-AAxm6cmzEE3Gmb41");
 
 
 MManual.deferredScripts.push("./bundles/redesign/mmanualdeferredjsv4.1.2.2-13178e13ca.js?v=-hMvtQA9NJy1WdyRhBfBFzrPaWL44SkinQI4pIY9AWk1");
 
 
 MManual.deferredScripts.push("./bundles/redesign/mmanualTopicdeferredjsv4.1.2.2-13178e13ca.js?v=wDzP134aC3i-5gwHvRAsARMyhcs_em3XWcSsRyzYpYQ1");
 
 MManual.utils.loadScripts(MManual.deferredScripts);
 }
 $(document).ready(downloadJSAtOnload);
</script>
<!--<![endif]-->
<!--[if lt IE 9]>
 
 <script src="/Content/Scripts/Lib/mediaelement-and-player.min.js?v4.1.2.2-13178e13ca" type="text/javascript"></script>
 <script src="/Content/Scripts/Lib/zoomerang.js?v4.1.2.2-13178e13ca" type="text/javascript"></script>
 <script type="text/javascript">
 function downloadJSAtOnload() {
 
 MManual.deferredScripts.push("/bundles/redesign/mmanualdeferredjsv4.1.2.2-13178e13ca.js?v=-hMvtQA9NJy1WdyRhBfBFzrPaWL44SkinQI4pIY9AWk1");
 
 
 MManual.deferredScripts.push("/bundles/redesign/ie8libsdeferredjsv4.1.2.2-13178e13ca.js?v=0HKp-yFnKaDEueCLP27J6D4rHb3-AAxm6cmzEE3Gmb41");
 
 
 MManual.deferredScripts.push("/bundles/redesign/mmanualTopicdeferredjsv4.1.2.2-13178e13ca.js?v=wDzP134aC3i-5gwHvRAsARMyhcs_em3XWcSsRyzYpYQ1");
 
 for (var i = 0; i < MManual.deferredScripts.length; i++) {
 var element = document.createElement("script");
 element.src = MManual.deferredScripts[i];
 element.classList.add("optanon-category-C0002");
 document.body.appendChild(element);
 }
 }
 $(document).ready(downloadJSAtOnload);
 </script>
<![endif]-->
 <!-- Current instance name : ue-p-sc-cd02
 Current application version : 4.1.2.2-13178e13ca
 -->
 <!--[if (gte IE 9)|!(IE)]><!-->
<script src="./bundles/redesign/libsEndjsv4.1.2.2-13178e13ca.js?v=NWrOPHpqntlKhYlvryw8nEPZpRaWQrScEY3i127KnfI1"></script>
<!--<![endif]-->
<input id="MediaFramework_ItemId" name="MediaFramework_ItemId" type="hidden" value="8421724D323B4C1EA65F97616EF1E639">
<div id="hiddentblcontents" style="display:none"></div></div><div id="hiddentblcontents" style="display:none"><div id='hidden_v936085'> <div data-mmanualobjecttype="Table" class="table-box"> <span id="v936087"></span> <div class="TableFullPage" id="v936085"> <h3 class="title">New York Heart Association (NYHA) Classification of Heart Failure</h3> <div class="tableWrapper"> <table> <thead><tr tablehead1=""><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v1386123" class="anchor"></span><div class="para"> <p>NYHA Class</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v1386124" class="anchor"></span><div class="para"> <p>Definition</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v1386125" class="anchor"></span><div class="para"> <p>Limitation</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v1386126" class="anchor"></span><div class="para"> <p>Example</p></div></p></th></tr></thead> <tbody><tr class="odd"><td><span id="v936101" class="anchor"></span><div class="para"> <p>I</p></div></td><td><span id="v936103" class="anchor"></span><div class="para"> <p>Ordinary physical activity does not cause undue fatigue, dyspnea, or palpitations.</p></div></td><td><span id="v936105" class="anchor"></span><div class="para"> <p>None</p></div></td><td><span id="v936107" class="anchor"></span><div class="para"> <p>Can complete any activity requiring <span class='symbol'>≤</span> 7 MET:</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v936110" class="anchor"></span><div class="para"> <p>Carry 11 kg up 8 steps</p></div></li><li class="topic__listitem"><span id="v936112" class="anchor"></span><div class="para"> <p>Carry objects weighing 36 kg</p></div></li><li class="topic__listitem"><span id="v936114" class="anchor"></span><div class="para"> <p>Shovel snow</p></div></li><li class="topic__listitem"><span id="v936116" class="anchor"></span><div class="para"> <p>Spade soil</p></div></li><li class="topic__listitem"><span id="v936118" class="anchor"></span><div class="para"> <p>Ski</p></div></li><li class="topic__listitem"><span id="v936120" class="anchor"></span><div class="para"> <p>Play squash, handball, or basketball</p></div></li><li class="topic__listitem"><span id="v936122" class="anchor"></span><div class="para"> <p>Jog or walk 8 km/hour</p></div></li></ul></div></td></tr><tr class="even"><td><span id="v936125" class="anchor"></span><div class="para"> <p>II</p></div></td><td><span id="v936127" class="anchor"></span><div class="para"> <p>Ordinary physical activity causes fatigue, dyspnea, palpitations, or angina.</p></div></td><td><span id="v936129" class="anchor"></span><div class="para"> <p>Mild</p></div></td><td><span id="v936131" class="anchor"></span><div class="para"> <p>Can complete any activity requiring <span class='symbol'>≤</span> 5 MET:</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v936134" class="anchor"></span><div class="para"> <p>Sexual intercourse without stopping</p></div></li><li class="topic__listitem"><span id="v936136" class="anchor"></span><div class="para"> <p>Garden</p></div></li><li class="topic__listitem"><span id="v936138" class="anchor"></span><div class="para"> <p>Roller skate</p></div></li><li class="topic__listitem"><span id="v936140" class="anchor"></span><div class="para"> <p>Walk 7 km/hour on level ground</p></div></li><li class="topic__listitem"><span id="v936142" class="anchor"></span><div class="para"> <p>Climb one flight of stairs at a normal pace without symptoms</p></div></li></ul></div></td></tr><tr class="odd"><td><span id="v936145" class="anchor"></span><div class="para"> <p>III</p></div></td><td><span id="v936147" class="anchor"></span><div class="para"> <p>Comfortable at rest; less than ordinary physical activity causes fatigue, dyspnea, palpitations, or angina.</p></div></td><td><span id="v936149" class="anchor"></span><div class="para"> <p>Moderate</p></div></td><td><span id="v936151" class="anchor"></span><div class="para"> <p>Can complete any activity requiring <span class='symbol'>≤</span> 2 MET:</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v936154" class="anchor"></span><div class="para"> <p>Shower or dress without stopping</p></div></li><li class="topic__listitem"><span id="v936156" class="anchor"></span><div class="para"> <p>Strip and make a bed</p></div></li><li class="topic__listitem"><span id="v936158" class="anchor"></span><div class="para"> <p>Clean windows</p></div></li><li class="topic__listitem"><span id="v936160" class="anchor"></span><div class="para"> <p>Play golf</p></div></li><li class="topic__listitem"><span id="v936162" class="anchor"></span><div class="para"> <p>Walk 4 km/hour</p></div></li></ul></div></td></tr><tr class="even"><td><span id="v936165" class="anchor"></span><div class="para"> <p>IV</p></div></td><td><span id="v936167" class="anchor"></span><div class="para"> <p>Symptoms occur at rest; any physical activity increases discomfort.</p></div></td><td><span id="v936169" class="anchor"></span><div class="para"> <p>Severe</p></div></td><td><span id="v936171" class="anchor"></span><div class="para"> <p>Cannot do or cannot complete any activity requiring <span class='symbol'>≥</span> 2 MET; cannot do any of the above activities</p></div></td></tr></tbody> <tfoot><tr><td colspan="4"><span id="v936175" class="anchor"></span><div class="para"> <p>MET = metabolic equivalent of task, a measure of how much energy is expended compared to remaining at rest.</p></div></td></tr></tfoot> </table> </div> </div> <button class="btn print" onclick="printPopupContent();"><i class="fa fa-print"></i></button> <button class="btn show-tab"><i class="fa fa-arrows-alt"></i><i class="fa fa-times"></i></button> </div></div></div><div id="hiddentblcontents" style="display:none"><div id='hidden_v936085'> <div data-mmanualobjecttype="Table" class="table-box"> <span id="v936087"></span> <div class="TableFullPage" id="v936085"> <h3 class="title">New York Heart Association (NYHA) Classification of Heart Failure</h3> <div class="tableWrapper"> <table> <thead><tr tablehead1=""><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v1386123" class="anchor"></span><div class="para"> <p>NYHA Class</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v1386124" class="anchor"></span><div class="para"> <p>Definition</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v1386125" class="anchor"></span><div class="para"> <p>Limitation</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v1386126" class="anchor"></span><div class="para"> <p>Example</p></div></p></th></tr></thead> <tbody><tr class="odd"><td><span id="v936101" class="anchor"></span><div class="para"> <p>I</p></div></td><td><span id="v936103" class="anchor"></span><div class="para"> <p>Ordinary physical activity does not cause undue fatigue, dyspnea, or palpitations.</p></div></td><td><span id="v936105" class="anchor"></span><div class="para"> <p>None</p></div></td><td><span id="v936107" class="anchor"></span><div class="para"> <p>Can complete any activity requiring <span class='symbol'>≤</span> 7 MET:</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v936110" class="anchor"></span><div class="para"> <p>Carry 11 kg up 8 steps</p></div></li><li class="topic__listitem"><span id="v936112" class="anchor"></span><div class="para"> <p>Carry objects weighing 36 kg</p></div></li><li class="topic__listitem"><span id="v936114" class="anchor"></span><div class="para"> <p>Shovel snow</p></div></li><li class="topic__listitem"><span id="v936116" class="anchor"></span><div class="para"> <p>Spade soil</p></div></li><li class="topic__listitem"><span id="v936118" class="anchor"></span><div class="para"> <p>Ski</p></div></li><li class="topic__listitem"><span id="v936120" class="anchor"></span><div class="para"> <p>Play squash, handball, or basketball</p></div></li><li class="topic__listitem"><span id="v936122" class="anchor"></span><div class="para"> <p>Jog or walk 8 km/hour</p></div></li></ul></div></td></tr><tr class="even"><td><span id="v936125" class="anchor"></span><div class="para"> <p>II</p></div></td><td><span id="v936127" class="anchor"></span><div class="para"> <p>Ordinary physical activity causes fatigue, dyspnea, palpitations, or angina.</p></div></td><td><span id="v936129" class="anchor"></span><div class="para"> <p>Mild</p></div></td><td><span id="v936131" class="anchor"></span><div class="para"> <p>Can complete any activity requiring <span class='symbol'>≤</span> 5 MET:</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v936134" class="anchor"></span><div class="para"> <p>Sexual intercourse without stopping</p></div></li><li class="topic__listitem"><span id="v936136" class="anchor"></span><div class="para"> <p>Garden</p></div></li><li class="topic__listitem"><span id="v936138" class="anchor"></span><div class="para"> <p>Roller skate</p></div></li><li class="topic__listitem"><span id="v936140" class="anchor"></span><div class="para"> <p>Walk 7 km/hour on level ground</p></div></li><li class="topic__listitem"><span id="v936142" class="anchor"></span><div class="para"> <p>Climb one flight of stairs at a normal pace without symptoms</p></div></li></ul></div></td></tr><tr class="odd"><td><span id="v936145" class="anchor"></span><div class="para"> <p>III</p></div></td><td><span id="v936147" class="anchor"></span><div class="para"> <p>Comfortable at rest; less than ordinary physical activity causes fatigue, dyspnea, palpitations, or angina.</p></div></td><td><span id="v936149" class="anchor"></span><div class="para"> <p>Moderate</p></div></td><td><span id="v936151" class="anchor"></span><div class="para"> <p>Can complete any activity requiring <span class='symbol'>≤</span> 2 MET:</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v936154" class="anchor"></span><div class="para"> <p>Shower or dress without stopping</p></div></li><li class="topic__listitem"><span id="v936156" class="anchor"></span><div class="para"> <p>Strip and make a bed</p></div></li><li class="topic__listitem"><span id="v936158" class="anchor"></span><div class="para"> <p>Clean windows</p></div></li><li class="topic__listitem"><span id="v936160" class="anchor"></span><div class="para"> <p>Play golf</p></div></li><li class="topic__listitem"><span id="v936162" class="anchor"></span><div class="para"> <p>Walk 4 km/hour</p></div></li></ul></div></td></tr><tr class="even"><td><span id="v936165" class="anchor"></span><div class="para"> <p>IV</p></div></td><td><span id="v936167" class="anchor"></span><div class="para"> <p>Symptoms occur at rest; any physical activity increases discomfort.</p></div></td><td><span id="v936169" class="anchor"></span><div class="para"> <p>Severe</p></div></td><td><span id="v936171" class="anchor"></span><div class="para"> <p>Cannot do or cannot complete any activity requiring <span class='symbol'>≥</span> 2 MET; cannot do any of the above activities</p></div></td></tr></tbody> <tfoot><tr><td colspan="4"><span id="v936175" class="anchor"></span><div class="para"> <p>MET = metabolic equivalent of task, a measure of how much energy is expended compared to remaining at rest.</p></div></td></tr></tfoot> </table> </div> </div> <button class="btn print" onclick="printPopupContent();"><i class="fa fa-print"></i></button> <button class="btn show-tab"><i class="fa fa-arrows-alt"></i><i class="fa fa-times"></i></button> </div></div></div></body>
<div class="bottomnav__gotolink bottomnav__gotolink--next"></div>  <div class="fixed-footer fixed-width" align="right" id="setbackgrnd"><table class="fixed-width"><tr class="fixed-width"><td id="tdsearch" align="right" class="tdsearch"><input type="text" id="search" onkeyup="search(id)" placeholder="Find on page..." class="form-control search"></td><td id="tdbtn" align="left" class="tdbtn"><button onclick="myFunction()" id="button" class="button"></button></td></tr></table></div>
</html>